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Chapter 1 
 
General introduction 
 
 
 
1.1. Composition and function of bone 
Bone is composed of living cells entrapped in an organic mineralized matrix. The cells in bone tissue 
contain osteoblasts (which are responsible for the formation and mineralization of bone), osteocytes, and 
osteoclasts (which are responsible for the resorption of bone). The detailed morphological characteristics and 
functions of these bone cells are shown in Table 1.1 . Bone matrix consists of organic components, mainly 
Type I collagen, and inorganic components, mainly hydroxyapatite (HA) and some other types of calcium 
and phosphate salts [1]. For the acellular part of bone tissue, over 30% of them are organic components, and 
about 70% of them are salts [3]. Collagen fibers provide bone tissue with the tensile strength, while the 
speckled crystals of HA provide bone with compressive strength [4].  
 
Table 1.1 The living cells in bone and their characteristics and functions (Source: refs [5, 6]). 
 
 
 
 
 
 
 
 
 
90-95% of the organic matrix of bone is Type I collagen and the rest of the matrix is a homogenous 
liquid called matrix that is composed of non-collagenous proteins (e.g., osteopontin, osteocalcin and bone 
sialoprotein) and proteoglycans (e.g., chondroitin sulfate and hyaluronic acid and). For better understanding, 
Table 1.2 shows a brief introduction to the main organic components of the bone matrix [2, 7]. The collagen 
fibers consist of the repeating unit that impart tensile strength to bone, and are aligned in an overlapping 
manner that can prevent the shear stress. The bone mineral (the inorganic component of bone) is primarily 
composed of calcium and phosphate salts and the main component is HA (formula: Ca10(PO4)6(OH)2) [1]. 
The accurate composition of the matrix can vary with time and nutrition, and the ratio of calcium to 
phosphate varies between 1.3 and 2.0 (mass ratio). Some trace minerals such as the sodium, carbonate, 
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magnesium and potassium can also being found in the bone matrix [1]. The composition of human bone is 
summarized in Fig. 1.1. 
 
Table 1.2. The composition of organic phase of the bone matrix (Source: refs [2, 5, 7]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bone tissue in adults has two forms of architecture [8]: trabecular bone (also known as cancellous or 
spongy bone) which is about 20% of the whole bone tissue, and compact bone (as known as cortical bone) 
which is about 80% of the whole bone tissue. Proportions of the two forms vary at different locations of the 
bone tissue. The compact bone is almost solid with only about 10% porosity. The compact bone can be 
further categorized into three different types: the short bones (ankle and wrist), the long bones (tibia and 
femur), and the flat bones (irregular bones and skull). The trabecular bone exhibits a higher porosity (ranging 
between 50–90%), with a modulus and ultimate compressive strength about 20 times lower than those of the 
compact bone [9]. The trabecular bone is arranged in a sponge-like morphology, with a honeycomb of 
various-sized branching bars, plates and rods named trabeculae. It’s generally presented in metaphysis of 
long bones, covered by compact bone, and in the vertebral arches. 
Bone tissue has a number of functions, including: a). Support: bones provide a framework for muscles 
and some other tissues. b). Movement: bones capacitate the body movements by serving as levers and 
attachment points of muscles. c). Protection: bones such as the rib cage and skull can prevent the internal 
organs from injuries. d). Hematopoiesis: the hematopoiesis (production of blood cells) happens in the red 
marrow in some bone cavities. e). Mineral storage: bones act as the reservoir for calcium and phosphate salts, 
and other essential minerals for diverse cellular activities. f). Energy storage: the lipids (e.g., fats) stored in 
the adipose cells of the yellow marrow can act as the energy reservoir. 
Fig. 1.1. Composition of human bone. Source: Chan et al. (2008) [1]. 
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1.2. Bone defects and bone repair 
A bone defect is a lack of bone tissue where it should normally occur. Bone injury caused by congenital 
malformations, aging, osteoporosis, traumatic infections, tumors, traffic accidents and other reasons is one of 
the major diseases that threaten human health. Reconstruction of large bone defects and non-unions has long 
been a significant clinical challenge in orthopedics [10]. Even though bone is one of the few regenerative 
tissues, some defect size is beyond the body’s self-healing capacity, so further intervention is required [11]. 
The critical size of bone defect depends on the cause and the location of the defect.  
In modern medicine, there are three main ways to repair bone defects: autologous bone graft, allogeneic 
bone graft and artificial bone graft. Autologous and allogeneic bone grafts are still the most common 
solutions in clinical applications. The autologous bone grafts use bones from another parts of the patient 
themselves, so that there is no immune rejection therefore a good bone repair result can be obtained. The 
autologous bone grafts have been the gold standard for bone replacement for several decades also since it can 
provide osteoblasts and essential osteoinductive factors that is required for bone healing [9, 12]. They are 
generally extracted from the trabecular bone of the iliac crests of the patients, while the compact bones can 
also be used [13, 14]. Nevertheless, the autologous bone grafts would cause the secondary trauma to the 
patient's body and increase the risk of hemorrhage, infection and damage the structural integrity of the 
patient. Moreover, the limited sources of the autologous bone cannot be used for the repair of defect bone 
tissue in large size [15]. Allogeneic bone grafts can be divided into allografts and xenografts. Allografts use 
the bones taken from living or dead bodies of other people. This method has some shortages such the limited 
sources, the immunological rejection and the risk of disease-spreading. Xenografts use the animal bones for 
the transplantation, although it’s easy to obtain the grafts, there are also some problems such as the immune 
rejection and disease transmission, therefore their applications have been greatly restricted [16, 17].  
To overcome the disadvantages of the autologous and allogeneic bone grafts, more and more attention 
has been drawn to artificial bone grafts. The artificial bone materials are easy to get and their performances 
can be designed and controlled [18]. Synthetic biomaterials used in the repair of bone defects have been 
massively investigated over the past few decades. But until now, the applications of artificial bone grafts are 
still much less than the autologous and allogeneic bone grafts. The reason for the restricted application of the 
artificial bone grafts is that their physical, mechanical and biochemical properties cannot yet totally meet the 
requirements of bone repair. Therefore, enhancing the comprehension of the interaction between artificial 
bone materials and organisms, improving characteristics of artificial bone materials and making them better 
applied to repair bone defects are urgent problems in contemporary materials science. Among all the artificial 
bone substitutes, metals and ceramics are most widely investigated [19]. Nevertheless, they all have some 
limitations. For example, metals, although they can provide immediately with the mechanical support at the 
defect sites, they usually exhibit insufficient integration with the surrounding tissues and may fail due to the  
infection and the fatigue loading [20]. Ceramics, on the other hand, have quite low tensile strength and are 
very brittle, so they cannot be applied in locations of significant bending, torsion or shear stress [21]. It is 
therefore clear that an appropriate bone substitute is yet to be found which is urgently needed for full 
recovery of the patients. A possible solution for these problems may be in bone tissue engineering.  
Bone tissue engineering is the strategy applying biotechnology in biomaterials to induce bone tissue 
regeneration, which is a complicated dynamic process that begins with cell migration and recruitment 
followed by cell proliferation, differentiation, matrix formation and finally the bone regeneration [22]. Three 
fundamental principles are included in bone tissue engineering, i.e., cells, bioactive molecules and scaffolds 
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which will gradually degrade and reabsorb as the tissue structures (Fig. 1.2) [23].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3. Principles of bone tissue engineering 
1.3.1. Scaffolds-temporary matrices for bone growth  
Every tissue is formed from (generally) many types of cells and a matrix. The matrix is a 
three-dimensional scaffold for cells in vivo and present a tissue-specific circumstance and structure [24]. In 
addition, it can serve as a reservoir of cytokines, growth factors, nutrients and water. For purpose of 
rebuilding functions or regenerating tissue, the scaffold, which would serve as the temporary matrix to 
initiate the cell proliferation as well as the deposition of the extracellular matrix (ECM) along with the bone 
regeneration, is needed [25, 26]. Furthermore, scaffold can also serve as the temporary matrix for the 
vascularization of the newly formed bone tissue [26, 27] and can take part in the remodeling process of bone 
tissue by releasing the differentiation or growth factors in situ in itself [28, 29]. 
Therefore, it’s reasonable that a proper 3D scaffold is a crucial part for the tissue engineering approach. 
Whereas, it’s considerable to recognize that the scaffold need to have many characteristics that are suitable 
for bone tissue engineering. An ideal scaffold not only requires to be with proper biocompatibility, 
biodegradability, porous structure and mechanical property, but also claims to be osteoconductive and 
osteoinductive [30, 31]. Scaffold with good osteoconductivity can stimulate the survival, migration and 
attachment of the osteogenic cells, while the osteoinductivity of the scaffold offers physical and chemical 
factors to promote the stem cells differentiate into osteoblastic lineage. 
1.3.1.1. Requirements of scaffolds  
The scaffolds need to meet the requirements as show below when they are applied in bone tissue engineering 
[25, 26, 32-34]:  
 
Fig. 1.2. Three fundamental principles in bone tissue engineering. 
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a).  Biocompatibility 
The scaffolds should integrate sufficiently in host's tissues without causing an immunological rejection. 
The scaffold should be biocompatible with cells cultured within them and the living tissue around it. 
Scaffolds should enable cells to attach and proliferate well, as well as maintain the cell-specific functions. 
Scaffolds and their degradation products should not be cytotoxic to cells and surrounding tissues after 
implantation. The implanted scaffold should not adversely affect the functions of the organ and the whole 
body. Besides, the inflammatory response to the implant should be prevented, and the formation of fibrous 
capsules that separate the implant from the surrounding tissue should be avoided to allow integration of the 
implant with the surrounding tissue. 
b). Biodegradability 
As we know, goal of bone tissue engineering is to make host's own cells can ultimately substitute the 
tissue engineered construct (the implanted scaffold) over time then eventually form the new bone tissue. 
Scaffold and construct in bone tissue engineering should not be served as the permanent structures. Therefore, 
scaffolds need to be biodegradable thus the cells can produce the ECM by themselves in situ of the implants 
[35]. Biodegradability is usually an important factor because the scaffold should be preferentially absorbed 
by neighboring tissues without the need for a further surgical invasion and removal. Degradation rate of the 
scaffold must be in consistent with the rate of tissue regeneration. That is to say, when the cells are producing 
the ECM surrounding themselves, scaffold must ensure the structural integrity. Meanwhile, scaffold needs to 
ultimately decompose, remaining the newly regenerated tissue which can bear the mechanical load [36, 37]. 
c). Mechanical property 
Ideally, the mechanical property of the scaffolds should be in accord with the anatomic sites where they 
are implanted. The strength of the scaffold must be sufficient to permit the surgical operation for the 
implantation. Although the mechanical property is very important for all the tissues, it offers certain specific 
challenges for the scaffolds used in orthopaedic applications. It’s one of the major challenges when design 
scaffold for bone tissue engineering that the scaffold needs to be with a sufficient mechanical property. When 
used in bone tissue engineering, the scaffold should remain competent mechanical stability to act properly 
from the initial implantation to end of the bone regeneration [38]. Another problem is that the remodeling 
rate of bone tissue varies with age. For the youths, the bone defects usually recover to point of the 
weight-bearing within 1.5 months, with the whole mechanical integrity recovering within one year. For elder 
people, the healing rate slows down. It also needs to be considered when design scaffold for the applications 
in bone tissue engineering.  
Nevertheless, as the field evolves, one may argue that researchers have paid too much attention to 
manufacture the scaffolds with the similar mechanical property to natural bones. Lots of scaffolds with good 
mechanical properties have been produced, but not conducive to maintaining high porosity. Many other 
scaffolds, which have shown good in vitro results, have failed after in vivo implanted because of the lacking 
vascularization capabilities caused by the low porosity of the scaffolds. Therefore, the balance between the 
mechanical property and the porous structures allowing cellular penetration and neovascularization is crucial 
for the final success of the scaffold for bone tissue engineering [39, 40]. 
d). Porosity 
Scaffold in bone tissue engineering must have highly porous structure with large ratio of the surface area 
to its volume, which facilitates cells to grow in as well as distribute homogeneously throughout the scaffold, 
as well as a better vascularization of the scaffold from the neighboring tissue. In addition, the scaffold should 
also exhibit sufficient micro porosity to allow for the ingrowth of the capillaries. Good interconnectivity and 
porosity are also crucial for the exact infiltration of the nutrients and oxygen, and also taking away the 
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metabolic waste resulted from the activity of the cells growing in the scaffolds. For the bone tissue 
engineering, this is of particular importance because high-rate mass transfer would occur resulting from the 
bone metabolic characteristics even under the in vitro cell culture conditions [41]. Moreover, the porosity 
would affect other characteristics of the scaffold (e.g., its mechanical property). In this case, the balance 
between the porosity and other properties of the scaffold should always be carefully considered.  
e).  Pore size 
The pore size of the scaffold is another critical issue. If the size of the pores is too small, the pore 
occlusion would happen when seeding cells on the scaffold, which further inhibit the cellular penetration, 
vascularization of the inner regions of the scaffold, and the sufficient production of extracellular matrix 
(ECM). For bone tissue engineering purposes, it is widely accepted that the pore size should between 200 
and 900 µm [34, 42]. Meanwhile, some researchers gave a different report [43]. Their studies supported the 
well-interconnected 3D scaffold with pores sizing between 1.2 and 2.0 mm would mostly facilitate the bone 
regeneration since the scaffold with those pores has obvious advantages due to the high ratio of surface to 
volume, which is beneficial for the in-growth of cells, blood vessels and tissues. Nevertheless, the large-sized 
macropores decreased the mechanical stability of the scaffold avoiding its usage in regions that need high 
mechanical property.  
f).  Surface properties 
Both the topographical and biochemical properties of the scaffold surface would affect the cellular 
adhesion and proliferation [44, 45]. The topographical properties of the scaffold are of special importance 
where the research is about osteoconduction. Since osteoconductivity is the process that the osteogenic cells 
from the surrounding tissues migrate to surface of the scaffold [45], it’s important that matrix of the scaffold 
is good for the migration after the scaffold implanted in vivo. Otherwise, when the cells begin the migration 
they will detach from the surface because of the wound contraction. It has been previously reported that the 
surface with higher roughness is better for cell attachment and migration than the smooth surface [46]. 
Chemical properties of scaffold surface are associated with the capacity of the cells to attach to scaffold and 
also the interactions with proteins.  
g).  Osteoconductivity 
Osteoconductivity means the bones grow on the surface of a scaffold. An osteoconductive scaffold 
allows bone tissue to grow on its surface and down into the pores, pipes or channels [46]. The bone growing 
on the implant surface relies on role of the differentiated osteocytes. These cells might be from the 
pre-existing preosteoblasts or the osteoblasts which are activated by trauma or cells that are recruited from 
the primitive mesenchymal cells via osteogenesis [47]. Therefore, under the practical circumstance, 
osteoconductivity depends to a quite large extent on the osteoinductivity (which will be describe later). In 
addition, without sufficient blood supply, the growth process of bone tissue will not happen. Albrektsson et al. 
investigated the in vivo bone remodeling, concluding that full vascularization is a necessary condition for 
bone formation [48]. However, as far as the implant is concerned, osteoconductivity depends not only on the 
conditions of the bone repair, but also on the biological material used and its reaction. For some materials 
such as copper and silver, it is not possible for the osteoconductivity [49]; While for other materials such as 
the stainless steel which is of poor biocompatibility, and the materials of high biocompatibility such as the 
titanium, osteoconductivity has been found [50].  
h).  Osteoinductivity  
Osteoinductivity of the scaffold means that the primitive, undifferentiated and pluripotent cells 
developed into the osteogenic lineage under the stimulation of scaffold [51]. Bone and the surrounding 
tissues contain many less differentiated cells, besides the differentiated bone cells including osteoblasts, 
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osteoclasts as well as the osteocytes. Those undifferentiated cells are most important for appropriate bone 
healing as they are able to be recruited to produce osteoprogenitors and to develop into differentiated bone 
cells over time [51] (Fig. 1.3). Undifferentiated mesenchymal cells could develop into the preosteoblast with 
the proper stimulus (osteoinductive cues), as a process which composes the bone induction. Many 
researchers have reported the osteoinductivity of some types of scaffolds in the last several decades [52, 53]. 
The bone tissue engineering scaffolds were implanted in anterior chamber of eyes or muscles, respectively, 
to prove the ectopic bone formation. The most reasonable way to prove one specific construct has 
osteoinductivity is to implant it in a ectopic position (e.g., muscle pouch, or subcutaneous implantation), and 
to analyze the possibility for new bone formation. Inducers also function naturally in the skeletal 
environment, but osteoinduction and osteoconduction are difficult to distinguish in situ. The osteoinductive 
agents also can function in situ of the bone defects, while it’s hard to distinguish between osteoinductivity 
and osteoconductivity of the agent in an orthotopic site. 
 
 
 
 
 
 
 
 
 
Osteoinductivity is the enrichment of the undifferentiated cells and the further development of those 
cells to preosteoblasts. Osteoinductivity is a fundamental mechanism which happens commonly, e.g., in 
incorporation of implant and bone defect healing. Though the pre-existing osteoblasts can contribute to the 
formation of the new bone tissue, it is normally believed that these preexisting cells contribute to only a 
small proportion of the newly formed bone [54, 55]. According to the study of Frost et al. [16, 17], the bone 
defect initiates the succeeding remodeling by sensitizing diverse kinds of cells. At the same time, the injured 
site will release topical, biophysical and biochemical signals to guide cells to respond in an appropriate 
manner. Those signals are divided into two parts. One part of these messengers are responsible for guidance 
of the differentiation and organization of the cells, while the other part of these messengers can provide the 
mitogens. The initial part of the healing procedure involves osteoinduction, which begins shortly after the 
injury and is most effective during the first week.  
1.3.1.2. Biomaterials used as bone tissue engineering scaffolds 
For bone tissue engineering applications, choosing the suitable material for fabrication of the scaffold is 
of particular importance since the characteristics of the material will directly decide the properties of the 
scaffold [23]. To date, several materials have been proposed to use in bone tissue engineering from both 
natural sources and synthetic sources, among which the ceramics, metals and polymers have been most 
commonly used. Nevertheless, most of the ceramics and all the metals are not biodegradable, reducing the 
researchers' choices to biodegradable polymers and a small amounts of ceramics. 
Fig. 1.3. After bone gets injured, both the undifferentiated and differentiated bone cells will be recruited to bone defect 
site. Most of the bone regeneration relys on the undifferentiated cells which can be developed into preosteoblasts. 
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Ceramics have been commonly applied in biomedical engineering, bone replacement and bone 
regeneration [56]. They can come from natural sources (e.g., coral HA) or synthetic sources (e.g., 
β-tricalcium phosphate (β-TCP), synthetic HA) [57]. They have been applied in bone tissue engineering 
contributing to their attractive characteristics, mainly the nature of being osteoinductive and osteoconductive. 
Good outcomes regarding new bone formation were obtained in several works by applying the ceramics with 
or without bone tissue related cells [52, 58, 59]. Whereas these works showed some major limitations. First 
of all, they have low mechanical stability and very brittle, which avoid their applications in bone 
regeneration of large bone defects. In addition, the rate of degradation or dissolution is unpredictable in vivo 
due to the multiple factors such as the osteoclastic activity that occurs in vivo. The rate of degradation can 
cause problems because if the degradation rate of the scaffold is too quick, mechanical stability of the 
scaffold will be decreased. At the same time, the extracellular concentration of the calcium and phosphorous 
would be dramatically increased, which would lead to the cell death [60].  
As another choose, the biodegradable polymers can be considered to be alternative materials for bone 
tissue engineering [26, 34]. These polymers can be categorized into two types: the natural type and the 
synthetic type. 
Natural biodegradable polymers are the polymers derived from the natural sources (i.e., animal source 
or plants). Among them, the most commonly used natural polymers are collagen [42, 61], chitosan [62, 63], 
fibrinogen [64, 65], hyaluronic acid [66, 67], starch [68, 69] and poly (hydroxybutyrate)(PHB) [70, 71]. 
Major advantages of the natural polymers are the low immunological response, non-toxic degradation 
products, potential bioactive behavior, the ability to interact with host tissues, biochemical versatility, and the 
unlimited sources. 
Synthetic biodegradable polymers are the biocompatible and biodegradable synthetic polymers most 
commonly used in the field of biomedical engineering. Their processability and biochemical versatility 
changes on the basis of their structures and natural properties, therefore it’s impossible to directly compare 
the synthetic polymers and the natural polymers. Among all the synthetic polymers, the most generally used 
polymers are poly anhydride) [72, 73], poly (phosphazenes) [74, 75], poly (ε-caprolactone) [76, 77], poly 
(α-hydroxy acids) ) [78, 79], poly (carbonate) [80, 81] and poly (propylene fumarate) [82-84]. 
1.3.1.3. Processing techniques 
After choosing the proper material for preparation of scaffold, the next step is to choose or develop the 
appropriate processing techniques. To realize this and to ensure that all scaffold properties are met, the 
optimized processing method needs to generally reach the following criteria [33]: 1. The processing method 
should not adversely affect the material's properties (e.g., its chemical properties or biocompatibility). 2. The 
processing method should be consistent and accurate with reference to pore size, porosity, pore distribution, 
interconnectivity and mechanical property. When processed from the same processing method with the same 
parameters and conditions, different scaffold batches should have minimal changes in their characteristics. 
Over the years, to fabricate scaffold with sufficient properties for bone tissue engineering, numerous 
processing techniques have been developed such as solvent casting [85, 86], phase inversion [43, 87], freeze 
drying [88, 89], rapid prototyping technologies [90-92], melt based technologies [2, 93], high pressure based 
methods [94, 95] and fiber bonding [96, 97]. These processing techniques are described and discussed below. 
Solvent casting (particulate leaching) may be the most well-known and commonly used method for 
fabrication of scaffolds for bone tissue engineering. Mikos et al. firstly described this method [98]. The 
method rests with dispersing calibrated inorganic (e.g., ice particulates, sodium tartrate, sodium chloride, 
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sodium citrate and effervescent salts) or organic (e.g., sucrose) particles in the polymer solution [85]. Further, 
the dispersive solution is casted or freeze-dried to make a scaffold with porous structure. Agrawal et al. 
developed the method with vibration in procedure of the polymer dissolution and the solvent evaporation. By 
this way, the ratio of porogen to polymer would be increased and the crystal deposition would be avoided 
[99]. The particulate leaching method was further developed by Murphy et al. by pouring the NaCl crystals 
to a mold and then exposed to 95% humidity for varied time so that the salt fusion could be obtained. The 
pore interconnectivity was increased by using this method [86]. The porous polymer matrix was finally 
produced after the salt particles were eventually leached out by the selective dissolution. The ratio of 
porogen to polymer determined the porosity while the size of porogen determined the size of the pores. By 
using the solvent casting method the fully interconnected scaffolds with high porosity (more than 90%) could 
be obtained [85, 86]. This technique has been applied in bone tissue engineering for preparation of porous 
scaffold from collagen, poly (lactide-co-glycolide) (PLGA) or poly (L-lactic acid) (PLLA) using ice 
particulates, dichloromethane or chloroform. The advantages of this method are that the pore size and the 
porosity of the prepared scaffolds can be independently controlled without use of any special equipments. 
Nevertheless, there are some limitations of this method. Since the porogen embedded in the polymer matrix 
needs to be removed completely, the thickness of the scaffold should to be limited within 2 mm. Furthermore, 
the agglomeration of the porogen in the polymer matrix might inhibit the formation of a homogeneous pore 
structure. If the organic solvents used in the fabrication procedure are not removed totally, the residuals may 
show cytotoxicity to the cells seeded on the scaffold and affect the efficiency of the bioactive molecules [100, 
101].  
Phase inversion is like the solvent casting method. Fig. 1.4a shows a PLGA scaffold prepared by using 
this technique. Instead of allowing solvent to evaporate which occurs in solvent casting method, the solution 
film is put in aqueous solution in the phase inversion method. This leads to a phase inversion that causes 
PLGA precipitation [43]. The major advantage of phase inversion method over the solvent casting is that it 
avoids crystal deposition and sample with thickness in excess of 3 mm can be produced. Scaffolds with 
morphologies similar with trabecular bone and higher interconnectivity were obtained by using this method 
[43, 87]. However, excluding improvement of the interconnectivity and thickness of the scaffolds, the other 
disadvantages presented in solvent casting remain in phase inversion method.  
Freeze-drying process depends on a thermal phase separation technique, which happens when the 
temperature of the polymer solution (which was injected to the mold in advance) is deceased. After the 
phase-separation system becomes stable, by using the vacuum sublimation the solvent-rich phase is excluded 
and a polymeric foam leaves behind. Both natural and synthetic polymer scaffolds have been fabricated by 
using this method [89]. By controlling the freezing rate, pH and freezing temperature, the pore structure of 
the scaffolds can be controlled [102]. This method can result in rather highly porous scaffolds. However, the 
heterogeneity of polymer matrix of the scaffolds, the random pore structure, the low mechanical stability and 
the technical sensitivity (process parameters should be well controlled) are the main drawbacks of this 
method [103, 104]. 
Rapid prototyping (RP), also called freeform fabrication (SFF) has been developed for bone tissue 
engineering with the advances in processing technology and computer [90]. This method can design and 
prepare complicated 3D scaffolds using the data obtained from digitizers, computer based medical imaging, 
computer assisted design (CAD) systems or the other data makers. The RP methods employ the layered 
manufacturing technique, by which the 3D scaffolds are produced layer by layer through the processing of 
liquid, powder or solid sheet material stocks. The computer dominated fabrication procedures, customized 
design and anisotropic scaffold microstructures are the major superiorities for their applications in bone 
tissue engineering. The most commonly used methods in the field are respectively the 3D printing [105, 106], 
3D plotting [107, 108], fused deposition modeling (FDM) [109, 110] and indirect RP approaches [90, 111]. 
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The representative examples of scaffolds prepared by RP techniques are shown in Fig. 1.4 (c and d). RP 
techniques allow the produce of complex, customized scaffolds with accurate and consistent pore structure as 
well as mechanical properties under the minimal manual handling and various kinds of processing conditions. 
Drawbacks of the RP techniques include: 1. The pore size of the manufactured scaffold depends on the size 
of the stock material powder; 2. The pore closure of the scaffold caused by the stock material; 3. Organic 
solvents are used as the binders for polymers; 4. The inappropriate mechanical properties since the final 
structure of the scaffolds is the stack-up of multiple layers [90, 112]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Melt based technique is another way to prepare scaffold for bone tissue engineering. One of such 
techniques is melt molding. In this method, the raw polymers are homogenously blended with the porogen 
materials in advance and then poured to molds, which are then heated above the glass transition temperature 
of the polymers. Afterwards, the porogen/polymer composites are immersed in the solvents for the selective 
dissolution of the porogens. By using this method the porous 3D scaffolds with different shapes are prepared 
Fig. 1.4. a). PLGA scaffold (OsteofoamTM) obtained by phase inversion. b). Starch-poly (lactic acid) (SPLA) scaffold 
prepared by using a method depended on extrusion with blowing agents. c). Chitosan scaffold prepared by a 3D 
plotting method. d). PCL/PEG scaffold prepared by Fused Deposition Modelling. Source: Salgado, A.J. et al. (2004) 
[2]. 
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by just changing the geometries of the molds [33, 97]. In addition, by altering the size and amount of the 
porogen materials, the method can also regulate the pore size and porosity of the prepared scaffolds [113]. 
Other melt based techniques for processing scaffolds for bone tissue engineering are injection and extrusion 
molding. These methods are relied on the blends of the raw polymers with blowing agents. After being 
mixed well, the blends undergo injection into or extrusion from the molds. The blowing agents degrade 
during the processing, releasing carbon dioxide and water which create the porous structure of the polymeric 
scaffolds [114, 115]. Based on these techniques, the scaffolds with a proper porosity and interconnectivity, as 
well as the morphologies similar to those of the natural trabecular bone have been fabricated, as shown in Fig. 
1.4 (b). Moreover, the mechanical properties (the compressive modulus and compressive strength) of these 
scaffolds are at the same level with the trabecular bone, and significantly higher than those of the scaffolds 
prepared by conventional techniques. In addition to good material properties from a material science 
perspective, the scaffolds also showed no cytotoxicity to cells, which facilitates the cell growth and 
deposition of extracellular matrix [68, 116]. The limitation of these methods is the restricted control of the 
pore distribution within the prepared scaffolds.  
High pressure processing depends on the CO2 saturation of the polymer discs by settling in the 
high-pressure CO2 [33, 117]. By decreasing the CO2 pressure to the ambient level, a thermodynamic 
instability is created resulting in the nucleation and expansion of the dissolved CO2 therefore generating 
marcopores. Scaffolds prepared using this method have been proved to support the growth of bone cells, as 
well as the deposition and mineralization of the bone matrix. On the other hand, there are still some 
disadvantages of this method such as the non-porous surface, the closed pore structure and the low 
mechanical stability of the prepared scaffolds, which can show some inhibition to the growth of bone cells 
and tissues.   
Fiber bonding is another scaffold processing method that fabricates the porous scaffold with variable 
pore size by weaving or knitting individual fibers into 3D patterns. Its major advantage is the large surface 
area of the prepared scaffolds which is good for both cell adhesion and the effective infiltration of nutrients 
[32, 118]. The porous 3D scaffold has been prepared by first aligning PGA fibers in the designed shape. 
Afterwards, the PGA fibers were immersed into a methylene chloride/PLLA solution [97]. After evaporation 
of the solvent, the PGA/PLLA composite scaffold was heated above the melting point of the two polymers. 
The PGA fibers are then physically connected at their cross-points by selective removal of the PLLA during 
cooling process. The main disadvantage of this technique are the immiscibility of the two polymers, the lack 
of control of pore size and porosity and the residues of solvent in the scaffold that can be detrimental to the 
cells and tissues [32]. 
1.3.2. Cells for bone tissue engineering  
After choosing the proper material and techniques for preparation of scaffold, the next step is to choice a 
reliable cells source for bone tissue engineering. An desired cells source needs to be non-immunogenic and 
easily expandable to larger amount, as well as have the certain pattern of protein expression which is similar 
to the in situ tissue needed to repaired [119]. 
1.3.2.1. Osteoblasts 
Due to the non-immunogenicity, the primary and most reasonable option of cell type for bone tissue 
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engineering is isolated osteoblasts from the biopsy obtained from patient (as the autologous cells) and then 
perform the restricted in vitro expansion. Nevertheless, this approach has some disadvantages: it takes time, 
quite small amount of the osteoblasts are useful after tissue dissociation and their rate of expansion is very 
low, restricting the cells amount available for seeding onto the scaffold. In addition, in some bone diseases, 
the osteoblasts cannot be suitable for the transplantation since the protein expression is below the anticipated 
value [120]. Another way to obtain the cells is by using the osteoblasts derived from the non-human donors 
(as the xenogeneic cells), which overcomes the limitation of low cell numbers. Nevertheless, the risk of 
transmission of infectious pathogens such as viruses, the immunogenicity of these cells and the ethical and 
social problems associated with them have inhibited the development of this method [120, 121]. 
To overcome the limitations of above-mentioned approaches, more and more attention has been drawn 
to stem cells. It has been a long time for the research of stem cells, and though some issues are yet to be 
answered, the use of the stem cells in bone tissue engineering can be regarded as a good alternative.  
1.3.2.2. Stem cells 
The stem cells are the undifferentiated cells remaining the high proliferative ability, being able to go 
through the self-renewal, multidirectional differentiation and thus the remodeling of the tissues [122]. 
Nevertheless, the stem cells have different extents of differentiation potential. The most primary stem cells 
are derived from zygote, more accurately from descendants of the very first divisions [123, 124]. Those cells 
are the totipotent cells due to their capacity of forming the embryo as well as the trophoblast of the placenta. 
After a few days, those cells became specialized, forming a hollow cell sphere, blastocysts and a bunch of 
cells named the Inner Cell Mass (ICM) (The embryo will be then derived from the ICM). The ICM cells, 
also called the embryonic stem cells (ES), are the pluripotent cells and are capable of differentiating into 
almost all cell types arisen by the three germ lines. In the end, the multipotent stem cells (also called adult 
stem cells, ASCs) are present in the fully differentiated tissues [125]. In theory, in contrast to ES, these cells 
produce only a restricted range of differentiation progeny associated with the embryo’s origin of the tissue 
where they are located. Whereas, in fact, these cells are proved to show a higher extent of differentiation 
plasticity.  
1.3.2.2.1. Embryonic Stem Cells 
As mentioned above, the embryonic stem cells (ES) locate in the ICM of blastocyst. To date, the ES 
cells have been isolated from human, primates and rodents [126]. The ES cells have been proved to 
differentiate to hematopoietic cells, cardiomyocytes, endothelial cells, neurons, ectodermal cells, hepatocytes, 
islets and chondrocytes [127]. Buttery et al. demonstrated that the osteoblasts could be differentiated from 
ES cells at presence of one specific osteogenic differentiation inducer-dexamethasone [128]. Nevertheless, 
though the ES cells have great potential in the applications for tissue engineering, some problems are still 
needed to be solved. First of all, it is necessary to develop methods that allow for direct differentiation, 
selective differentiation and integration, and the somatic tissue-specific functions of ES cells upon 
transplantation [129]. Second, it has been ensured that the undifferentiated ES cells can increase the risk for 
teratocarcinomas and teratomas after in vivo implantation since their proliferative capability is unlimited. 
Therefore, it’s an issue to ensure the ES-cell-derived somatic donor cells are not tumorigenic. The third 
problem needed to be solved is the immunological of the cells. 
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1.3.2.2.2. Adult Stem Cells 
The stem cells located in the fully differentiated tissues are the so-called adult stem cells (ASCs) [130]. 
Until now the ASCs have been found in bone marrow [131], adipose [132], muscle [133], periosteum [133], 
skin [134] and brain [134]. In the field of bone tissue engineering, the stem cells resided in the bone marrow, 
called as the Mesenchymal Stem Cells (MSCs), are of particular interest. Caplan et al. reported that when 
these cells are placed under appropriate culture conditions, they can differentiate to cells with mesenchymal 
origin and form bone, tendon, muscle, adipose, cartilage and skin [135, 136]. In addition to the 
differentiation potential, the MSCs can also show other features. Bruder et al. reported that the extensive 
expansion of the MSCs can be obtained in vitro [137]. As described by Pittinger et al., the MSCs did not 
differentiate spontaneously as the increased number of passages [135, 136]. Besides, it was suggested that 
these cells showed immunosuppressive effects in vivo that made them available for allogeneic or xenogeneic 
transplantation [138]. Currently, for the applications in bone tissue engineering, the MSCs have shown more 
achievements than those of ES cells. The MSCs have been used in clinical trials of certain applications [139], 
while for ES cells it is still a long way from reaching this stage. Whereas, it has to be noted that the ES cells 
will be a huge cells source for bone tissue engineering once the related issues are solved. 
1.3.3. Bioactive molecules 
Bioactive molecules such as growth factors and small molecular-weight drugs are employed in tissue 
engineering to control cell functions as well as the formation of tissues. Growth factors are the most 
commonly used bioactive molecules that affect cell proliferation, differentiation and morphogenesis. Growth 
factors are usually proteins which are secreted by cells and act as the cell-signaling molecules [13]. Bonding 
of growth factors with their receptors triggers intracellular signaling which leads to diverse events such as 
promoting and/or preventing the cell migration, adhesion, proliferation, and differentiation via up- or 
downregulating the production of certain growth factors or receptors [121, 140]. Similar to other tissues, 
bone tissues also have plenty of growth factors. Among those, the bone morphogenetic proteins (BMPs), 
fibroblast growth factor (FGF), transforming growth factor beta (TGF-β), platelet derived growth factor 
(PDGF) and insulin growth factor I and II (IGF I/II) are most commonly used in the applications for bone 
tissue engineering [141, 142].  
Here gives a brief introduction to the most commonly used growth factors in bone tissue engineering. 
First is the BMPs. BMPs are usually embedded in bone matrix which are usually expressed in the early 
stages of bone defect remodeling [143]. The key role of BMPs is to recruit MSCs to the healing site and then 
stimulate the differentiation of these MSCs to osteogenic lineage. It’s not yet fully understood of the 
mechanisms by which the BMPs act on MSCs. While, it has been accepted that the BMP-2 has a significant 
function in expression of osteogenic markers such as the osteocalcin (OCN) and the alkaline phosphatase 
(ALP) via mitogens activated protein kinase (MAPK) pathway [144]. The BMPs may also be associated in 
the expression of nuclear transcription factor Cbaf-1/Runx2 [145].  
Another widely used growth factor is TGF-β. The biological effects of TGF-β are diverse. The TGF-β 
has been found to facilitate the cell proliferation, hypertrophy and differentiation in vitro [146]. It has also 
been proved that TGF-β can block or initiate cell migration and differentiation. It enhances the collagen 
production and the proliferation of osteoblast-like cells in vitro. Moreover, TGF-β has been shown to 
increase the callus formation at the facture healing sites in some in vivo studies [147].  
IGF genes are expressed by skeletal cells. Although IGF I and II have similar effects on bone 
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metabolism, IGF I has been approved to be more effective than IGF II [148]. After injury the IGFs can be 
found at the fracture site to stimulate the synthesis of collagen type I, as well as promote the deposition of the 
extracellular matrix [149]. Moreover, by reducing collagen synthesis or the expression of the stromal 
collagenase in osteoblasts, the IGFs can maintain the collagen integrity in the bone microenvironment [148]. 
In addition to the above-mentioned growth factors, other growth factors may also be employed in bone 
tissue engineering. Vascular endothelial growth factor (VEGF) is an angiogenic factor that is expressed in the 
vascularized tissues. It is commonly presented at fracture healing sites to regulate the vascularization by 
recruiting the endothelial cells to the sites. VEGF can also regulate the interaction between angiogenesis and 
osteogenesis at the fracture healing sites. Besides VEGF, the FGF-2 is another cytokine related to the process 
of bone remodeling.  
The FGF-2 is associated with the delicate balance between the bone-forming cells and the 
bone-resorbing cells [150]. The FGF-2 can also enhance the neovascularization and stimulates the osteogenic 
phenotype by activating Cbaf-1/Runx2 nuclear transcription factors [142]. Moreover, the PDGF, which 
produced by osteoblasts, monocytes/macrophages or platelets, also plays a role in bone regeneration. It is 
also thought to stimulate the migration of MSCs towards the facture healing site [151].  
Although up to now the protein growth factors are mostly common used, there are many shortages of 
growth factors such as the limited sources, the high price, short half-life, easy-lost activity and risk of tumors 
[152]. To solve those problems, some researchers has been trying to use single component, safe, stable and 
inexpensive low-molecular-weight bioactive molecules to substitute the role of protein growth factors. One 
of such low-molecular-weight bioactive molecules used in bone tissue engineering is dexamethasone (DEX). 
DEX is a kind of glucocorticoid with highly potent and long-acting property [153]. As an earliest known and 
readily available osteogenic inducer for MSCs, DEX plays a key role in controlling regulation of osteogenic 
marker genes [154]. Moreover, DEX has antiallergic, antitoxic, antishock, antipyretic and 
immunosuppressive properties and can inhibit secretion of pro-inflammatory cytokines, including IL-1β, 
IL-6, INF-γ and TNF-α [155]. MSCs cultured with continuous DEX treatment exhibited higher expression 
levels of osteogenic markers and higher positive rates of osteogenic colony formation than those without 
DEX treatment [156]. 
1.4. Bone tissue engineering strategies  
Many efforts have been made to prepare the scaffolds for bone tissue engineering. To mimic extracellular 
matrix composition of bone, a variety of strategies have been considered, including usage of the components 
present in natural bone [10], controlling of pore structure and interconnectivity [157], construction of 
multiple scale architectures [158] and incorporation of growth factors [159]. For example, calcium phosphate 
(CaP) has been hybridized with polymers in the forms of tablets [160], blends [161], pastes [162] or cements 
[163]. However, these CaP/polymer composite scaffolds do not have appropriate pore structures for cell 
accommodation and migration. In particular, their pore interconnectivity is poor [164, 165]. 
To render scaffolds with good osteoinductivity, growth factors have been incorporated in the scaffolds. 
Nevertheless, the most commonly used growth factors such as bone morphogenetic proteins (BMPs) and 
transforming growth factor beta (TGF-β) are proteins and can easily lose their bioactivity during the 
preparation procedures [166]. To minimize denaturation and maintain their bioactivity, growth factors are 
generally introduced in scaffolds by physical adsorption. The release of physically adsorbed proteins always 
exhibits an initial burst and cannot last for a long period [167-169]. On the other hand, dexamethasone 
(DEX), as a low molecular weight osteoinductive factor, has drawn much attention for incorporation in 
scaffolds for bone tissue engineering because of its high stability even in tough chemical environment [170]. 
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DEX and hydroxyapatite (HA) nanoparticles have been hybridized with gelatin and poly(L-lactide) to 
construct hydroxyapatite/DEX/PLLA/gelatin composite scaffold by electrospinning technique [171]. There 
are some limitations in this work. For instance, the PLLA/gelatin hybrid scaffold was prepared by 
electrospinning technique, which resulted in uneven distribution of nanofibers, the low thickness and low 
mechanical of the scaffold. Such scaffold cannot offer a proper 3D environment for cell proliferation, 
migration and differentiation. Besides, the PLLA were used in the dexamethasone (DEX) delivery system. 
As we know, the major concerns associated with biodegradable synthetic polymeric drug delivery systems 
are the acidic or degradation by-products that alter the drug activity, and even can adversely interact with the 
drug or tissue as they come in contact during circulation. Moreover, to load the DEX into the scaffold, the 
DEX was primarily dissolved in DMF then mixed with nanocomposite of PLLA and nHA. The DMF is with 
high cytotoxicity, so how to completely remove the organic solvent remains to be solved.  
In another work, the DEX-loaded mesoporous silica nanoparticles have been deposited onto 
poly(L-lactic acid)/poly(ε–caprolactone) nanofibrous scaffold by electrophoretic deposition [172]. Besides 
the disadvantage of using synthetic polymers in the system as described above, there are some other 
drawbacks in this work. First, the prepared scaffolds showed very low interconnectivity, which was no good 
for the penetration of cells, nutrient, oxygen, growth factors and wastes flow through the scaffold [173, 174]. 
Second, to load the DEX to the MSNs-NH2, the MSNs-NH2 were soaked in the DEX solution. In other words, 
the DEX were just coated on surface of the MSNs-NH2. The burst release of DEX showed at the first 5 days, 
and after 7 days there was almost no further release of DEX. 
A dual delivery system of DEX and BMP-2 has been designed via co-electrospinning the blending 
solution that is composed of BMP-2-encapsulated bovine serum albumin nanoparticles, DEX and PCE 
copolymer [175]. In this work, besides the disadvantages of using synthetic polymer (PCE) and 
electrospinning technique as described above, the other drawbacks are as follows: First, to prepare the 
BMP-2-loaded chitosan-stabilized BSA nanoparticles (BNPs), the BMP-2 was primarily added to the BSA 
solution, then 40 mL ethanol was pumped into the 1% BSA solution. Then, 40 mL of chitosan solution (1 
mg/mL, dissolved in 1% acetic acid solution) was added to the mixture, and ethanol was pumped into the 
mixture at 0.5 mL/min. The formed BNPs were collected by centrifugation and washed with 50/50 distilled 
water/ethanol (v/v) solution. As we know, BMP-2 is protein, which easily loses the bioactivity under some 
extreme conditions (ethanol, acidic solution) [176]. Considering BMP-2 is very expensive, the method for 
loading BMP-2 in this article is inappropriate since the BMP-2 was exposure to ethanol; Second, the BMP-2 
showed a burst release. We know it’s unsafe when exposing body to high dosages of growth factors and this 
might even increase the risks for tumors, therefore the clinical potential of the prepared nanofibers is limited; 
Third, the DEX-loaded nanofibers display a typical initial burst release of DEX due to the DEX located in 
the external surface formed by its dissolving out or phase separation at the nanofiber surface, and the DEX 
release only sustained for 8 days.   
1.5. Motivation, objectives and outline 
1.5.1. Motivation and objectives 
Bone defect has become one of the big menaces in human daily life. Although bone is one of the few 
regenerative tissues in human body, its regenerative ability is limited. Some bone defects undergo incomplete 
fracture healing (nonunion fractures) and sometimes the defect size is beyond the body’s healing capacity (critical 
size defects). Therefore, further intervention is required to treat these fractures and defects. At present, autologous 
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and allogenic bone grafts are the two main choices to replace the damaged bone. However, both of them have 
many problems such as limited autologous donor tissues, donor site morbidity and immunological rejection of 
allogenic grafts. Instead, a number of artificially synthesized biomaterials such as ceramics, alloys and polymers 
have been developed for the repair of bone defects. Although these biomaterials are osteoconductive, they 
generally do not have osteoinductive capacity. On the other hand, osteoinductive cues such as bone growth factors 
are able to induce bone formation, even in nonskeletal sites (e.g., muscle). Hence, combination of an 
osteoconductive biomaterial with osteoinductive cues is supposed to overcome the limitations of conventional 
bone graft biomaterials. Such composite biomaterials can have both osteoconductive and osteoinductive capacities 
and accelerate bone formation and regeneration when implanted.  
Protein growth factors are most commonly used as osteoinductive cues. However, they havesome shortages 
such as limited sources, high price, short half-life and easily lost activity. One way to solve those problems is 
using stable and inexpensive low-molecular-weight molecules to substitute the role of protein growth factors. One 
of such low molecular weight molecules used for bone regeneration is dexamethasone (DEX). DEX is a kind of 
glucocorticoid with high potency and long-acting property. As one of the earliest known and readily available 
osteogenic inducers for mesenchymal stem cells (MSCs), DEX plays a key role in controlling expression of 
osteogenic marker genes. MSCs cultured with continuous DEX treatment exhibit higher expression level of 
osteogenic markers and a higher positive rate of osteogenic colony formation than those without DEX treatment. 
To date, several DEX delivery methods are available, ranging from systemic injection, eluting coating, and 
loading within biodegradable polymer carriers. Nevertheless, systemic injection has the obvious disadvantage of 
exposing the whole body to high dosage of the drug. Release of DEX from eluting coatings can neither last as 
long as the required period for biomedical application nor release appropriate dose in response to the dynamic 
change of the local biochemical environment.  
Compared with biodegradable polymer carriers, calcium phosphate nanoparticles (CaP NPs) have been 
showing enormous potential as carriers of osteoinductive factors because CaP NPs are the inorganic component of 
natural bone. CaP NPs are biocompatible and biodegradable, which are essential properties for drug carriers. 
Furthermore, synthesis of CaP NPs is a straightforward precipitation process. Incorporation of drug molecules 
only requires molecules of interest be present during the particle formation. Hence, CaP NPs have been widely 
used as carriers for drugs, proteins, DNA and RNA. Therefore, in this study CaP NPs were used to load DEX and  
the DEX-loaded CaP NPs were hybridized with collagen sponges to prepare their composite scaffolds. The 
composite scaffolds were used for culture of human bone marrow-derived MSCs (hMSCs) to investigate their 
effects on osteogenic differentiation of hMSCs and bone regeneration. 
1.5.2. Outline 
The DEX loaded calcium phosphate nanoparticles/collagen scaffold were prepared for bone tissue 
engineering. The cell proliferation and osteogenic differentiation were checked in both in vitro and in vivo 
environments.  
In Chapter 2, DEX was incorporated in biphasic calcium phosphate nanoparticles (BCP NPs) by immersion 
method and precipitation method to prepare DEX-loaded BCP NPs (DEX@BCP NPs). The release profile of DEX 
and their effects on the osteogenic differentiation of hMSCs were investigated. The parameter for preparation of 
the DEX@BCP NPs was optimized to obtain the final DEX@BCP NPs. The DEX@BCP NPs were used for cell 
culture of hMSCs to check their osteogenic differentiation.  
In Chapter 3, the potential applications of the above prepared DEX@BCP NPs in bone tissue engineering 
were explored. Composition of natural bone is about 35% organic (primarily collagen type I) and 65% inorganic 
(nanocrystalline calcium phosphate, CaP). So, in this part, the DEX@BCP NPs were hybridized with porous 
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collagen sponge of which pore structure was controlled by using pre-sieved ice particulates as a porogen material. 
Potential of the DEX@BCP NPs/collagen composite scaffolds (DEX@BCP/Col) for osteogenesis was 
investigated both in vitro and in vivo.  
In Chapter 4, the prepared DEX@BCP/Col were further developed for better angiogenesis and osteogenesis. 
In the previous research, we found that the DEX@BCP/Col scaffold showed the osteogenesis starting from the 
peripheral regions, and even after 12 weeks of subcutaneous implantation the osteogenesis of the central regions 
of the scaffolds was not sufficient. Because of the critical role of blood vessels on osteogenesis of tissue 
engineering scaffolds, lack of sufficient mature vascular networks should be responsible for the deficiency of the 
osteogenesis at the central regions of the DEX@BCP/Col. So, in this part, for simultaneous enhancement of 
angiogenesis and osteogenesis, DEX@BCP/Col composite scaffolds with concave microgroove network were 
designed and prepared. The microgroove network in the composite scaffolds were supposed to guide assembly of 
human umbilical vascular endothelial cells (HUVECs) into well aligned tubule-like structures, thus promoting 
rapid angiogenesis and osteogenesis.  
In Chapter 5, the conclusions of this thesis are given and the future prospects were addressed.  
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Preparation of dexamethasone-loaded biphasic calcium phosphate 
nanoparticles for osteogenic differentiation of human mesenchymal 
stem cells 
 
 
 
 
2.1 Summary 
As an earliest known and readily available osteogenic inducer for stem cells, DEX plays a key role in 
affecting cell functions and cellular processes, especially for cell proliferation and differentiation. However, 
the clinical application of DEX has been limited because of its uncontrolled release. An ideal carrier is 
desired to control DEX release for osteogenic differentiation of stem cells and bone tissue engineering. 
Biphasic calcium phosphate nanoparticles (BCP NPs) should be a potential carrier for DEX due to their 
osteoconductive property and good biocompatibility as a bone graft biomaterial. In this part, DEX-loaded 
BCP NPs were prepared by two methods: (1) immersion of BCP NPs in a DEX solution (defined as 
DEX/BCP NPs), (2) DEX incorporation during BCP NPs formation in a calcifying solution (defined as 
DEX@BCP NPs). The DEX@BCP NPs showed higher DEX loading amount and more sustainable DEX 
release than did the DEX/BCP NPs. The DEX@BCP NPs were used for culture of hMSCs and showed a 
promotive effect on proliferation of hMSCs. Furthermore, the DEX@BCP NPs significantly increased the 
alkaline phosphatase (ALP) activity, calcium deposition and gene expressions of osteogenic markers of 
hMSCs when compared to BCP NPs without DEX loading. The results demonstrated BCP NPs are a good 
carrier for DEX loading and the DEX@BCP NPs should have useful guidance for bone tissue engineering. 
2.2 Introduction 
Bone defect has become one of the big menaces in human daily life. Although bone is one of the few 
regenerative tissues in human body, its regenerative ability is limited [1]. Some bone defects undergo 
incomplete fracture healing (nonunion fractures) and sometimes the defect size is beyond the body’s healing 
capacity (critical size defects) [2, 3]. Therefore, further intervention is required to treat these fractures and 
defects. At present, autologous and allogenic bone grafts are the two main choices to replace the damaged 
bone. However, both of them have many problems such as limited autologous donor tissues, donor site 
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morbidity and immunological rejection of allogenic grafts [4]. Instead, a number of artificially synthesized 
biomaterials such as ceramics, alloys and polymers have been developed for the repair of bone defects [5-7]. 
Although these biomaterials are osteoconductive, they generally do not have osteoinductive capacity [8, 9]. 
On the other hand, osteoinductive cues such as bone growth factors are able to induce bone formation, even 
in nonskeletal sites (e.g., muscle) [10]. Hence, combination of an osteoconductive biomaterial with 
osteoinductive cues is supposed to overcome the limitations of conventional bone graft biomaterials. Such 
hybrid biomaterials can have both osteoconductive and osteoinductive capacities and accelerate bone 
formation and regeneration when implanted.  
Protein growth factors are most commonly used as osteoinductive cues. However, there are some 
shortages of protein growth factors such as the limited sources, high price, short half-life and easily lost 
activity [11, 12]. One way to solve those problems is using stable and inexpensive low-molecular-weight 
molecules to substitute the role of protein growth factors. One of such low molecular weight molecules used 
for bone regeneration is dexamethasone (DEX). DEX is a kind of glucocorticoid with high potency and 
long-acting property [13]. As one of the earliest known and readily available osteogenic inducers for 
mesenchymal stem cells (MSCs), DEX plays a key role in controlling expression of osteogenic marker genes 
[14]. MSCs cultured with continuous DEX treatment exhibit higher expression level of osteogenic markers 
and a higher positive rate of osteogenic colony formation than those without DEX treatment [15]. To date, 
several DEX delivery methods are available, ranging from systemic injection [16], eluting coating [17, 18], 
and loading within biodegradable polymer carriers [19, 20]. Nevertheless, systemic injection has the obvious 
disadvantage of exposing the whole body to high dosage of the drug, while the release of DEX from eluting 
coatings can neither last as long as the required period for biomedical application nor release appropriate 
dose in response to the dynamic change of the local biochemical environment.  
Compared with biodegradable polymer carriers, calcium phosphate nanoparticles (CaP NPs) have been 
showing enormous potential as carriers of osteoinductive factors because CaP NPs are the inorganic 
component of natural bone. CaP NPs are biocompatible and biodegradable [21, 22], which are essential 
properties for drug carriers. Furthermore, synthesis of CaP NPs is a straightforward precipitation process. 
Incorporation of drug molecules only requires molecules of interest be present during the particle formation 
[23-25]. Hence, CaP NPs have been widely used as carriers for drugs [26, 27], proteins [28, 29], DNA and 
RNA [30, 31]. Nevertheless, to our knowledge, no literature has reported the application of CaP as the carrier 
of DEX. Therefore, in this study DEX was incorporated in biphasic calcium phosphate nanoparticles (BCP 
NPs) by immersion method and precipitation method to prepare DEX-loaded BCP NPs. The release profile 
of DEX and their effects on the osteogenic differentiation of human bone marrow-derived MSCs (hMSCs) 
were investigated. 
2.3 Materials and methods 
2.3.1 Materials 
Calcium nitrate tetrahydrate (Ca(NO3)2·4H2O, 99.9%), ammonium phosphate dibasic ((NH4)2HPO4, ≥
98.0%), dexamethasone (C22H29FO5, ≥ 97%), ammonium hydroxide solution (NH4OH, 28.0~30.0%), 
Dulbecco’s Modified Eagle’s Medium (DMEM), penicillin, streptomycin, β-glycerophosphate, alizarin Red 
S, 2-amino-2-methyl-1,3-propanediol, naphthol AS-MX phosphate, fast blue RR salt, trypsin/EDTA were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS) was purchased from Gibco 
Lab. (Grand Island, NY, USA). Hydrochloric acid and 4% paraformaldehyde were purchased from Wako 
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Pure Chemical Industries, Ltd. (Tokyo, Japan). WST-1 reagent was obtained from Roche Molecular 
Biochemicals (Mannheim, Germany). Cellstain Live-Dead Double Staining kit was purchased from Dojindo 
Lab. (Kumamoto, Japan). Pierce® BCA Protein Assay Kit was purchased from Thermo Fisher Scientific Inc. 
(Rockford, USA). Sensolyte® pNPP Alkaline Phosphatase Assay Kit was purchased from AnaSpec Inc. 
(California, USA). RNeasy Mini Kit was purchased from Qiagen (Hilden, Germany). All the chemical 
reagents were used as received without further purification. The water used in all the experiments was 
ultrapure water with a resistivity of 18.2 MΩ.cm purified by a Q-POD Milli-Q water purification system 
(Millipore Corp., Billerica, MA, USA). 
2.3.2 Synthesis of BCP NPs and DEX-loaded BCP NPs 
Biphasic calcium phosphate (HA/TCP = 60/40, theoretical value) nanoparticles (BCP NPs) were 
synthesized according to a previously reported method with some modifications [32]. 50.0 mL of 0.5 M 
calcium nitrate tetrahydrate solution was added dropwise to 33.4 mL of 0.5 M ammonium phosphate dibasic 
solution at a speed of 150 mL/h by a syringe pump (KD Scientific Inc., USA). The reaction was conducted in 
a 55 °C water bath under magnetic stirring (700 rpm). The pH value in the reaction solution was real-time 
monitored by an F-23 pH/ION meter (HORIBA Ltd., Japan). Ammonium hydroxide solution was added 
dropwise to the reaction solution during the whole reaction procedure to keep the pH value to be 9.5.  After 
that, the reaction was maintained for another 30 minutes in the 55 °C water bath at the same stirring speed. 
Subsequently, the slurry was kept at room temperature for 36 hours for an aging process to form the stable 
BCP NPs.  
Based on the BCP NPs preparation procedure, two methods were used to load DEX in the BCP NPs. 
For the first method, the BCP NPs were prepared and then immersed in an ethanol solution of DEX with 
different concentrations. The ethanol solution of DEX was prepared by dissolving different amount of DEX 
(0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5 and 5.0 mg) in 2 mL ethanol. The mixture solution was further stirred 
by a magnetic stirrer (700 rpm) at room temperature for 50 minutes to prepare the DEX-loaded BCP NPs 
(defined as DEX/BCP NPs). For the second method, DEX was incorporated during the formation of the BCP 
NPs. At first, different amount of DEX (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5 and 5.0 mg) was dissolved in 
2 mL ethanol. The 2-mL ethanol solution of DEX was added to 48.0 mL of 0.52 M calcium nitrate 
tetrahydrate aqueous solution. Subsequently, the mixture solution of DEX and calcium nitrate tetrahydrate 
was added dropwise to 33.4 mL of 0.5 M ammonium phosphate dibasic solution in a 55 °C water bath under 
magnetic stirring (700 rpm). Ammonium hydroxide solution was added dropwise to the reaction solution 
during the whole reaction procedure to keep the pH value to be 9.5. The reaction was maintained for another 
30 minutes in the 55 °C water bath at the same stirring speed. Finally, the reaction was kept at room 
temperature for 36 hours for aging to get the slurry of DEX-loaded BCP NPs (defined as DEX@BCP NPs). 
The BCP NPs, DEX/BCP NPs and DEX@BCP NPs prepared above were collected by centrifuging the 
respective slurries at 8000 rpm for 5 min and washed with Milli-Q water for more than five times until the 
pH value of the supernatant liquid returned to 7. The NPs were re-dispersed in Milli-Q water and stored at 
4 °C for further use.  
The morphology of the prepared NPs was observed with a JEOL 2100F transmission electron 
microscope (TEM, JEOL, Tokyo, Japan) with an operating voltage of 200 kV. The TEM samples were 
prepared by dropping 8 μL of the NPs solution onto a carbon-covered copper grid, following by drying in air. 
Hydrodynamic size and zeta potential measurements were performed on a DelsaTM Nano C Particle 
Analyzer (Beckman Coulter, Fullerton, CA, USA). The X-ray diffraction (XRD) patterns of the NPs were 
characterized using a Rigaku Rint-2000 Ultima III X-ray diffractometer (Rigaku, Tokyo, Japan). 
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2.3.3 Measurement of DEX loading amount and in vitro release profile 
To measure the DEX loading amount, 10 mg DEX/BCP NPs or DEX@BCP NPs prepared with different 
initial feeding amount of DEX were dissolved in 0.3 mL 1 M HCl. And then 1.7 mL PBS (pH 7.4) was 
added to dilute the samples. The DEX concentration in the samples was determined by using a UV-vis 
spectrophotometer (Jasco Corp., Tokyo, Japan) at 242 nm with a calibration curve of free DEX. The loading 
amount was calculated from the concentration, solution volume and amount of DEX/BCP NPs or 
DEX@BCP NPs. The loading efficiency of DEX was calculated by dividing the loading amount with the 
initial feeding amount of DEX. In vitro release of DEX from the DEX/BCP NPs or DEX@BCP NPs was 
carried out in PBS solution (pH 7.4). The DEX/BCP NPs or DEX@BCP NPs (20 mg) were suspended in 1 
mL of PBS. The suspension solution of DEX/BCP NPs or DEX@BCP NPs was transferred to dialysis bags 
(cut-off molecular weight: 1000 Da) and the bags were placed in centrifuge tubes containing 4 mL PBS. The 
tubes were shaken at a speed of 60 rpm at 37 °C. At time points of 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 
5, 7, 9, 11, 13, 15, 17, 19 and 21 days, the amount of DEX released in the PBS was monitored via a UV-vis 
spectrophotometer at 242 nm. Percentage of DEX released from the DEX/BCP NPs or DEX@BCP NPs was 
calculated by dividing the total amount of released DEX with the loading amount of DEX. At each time 
point, three samples of DEX/BCP NPs or DEX@BCP NPs were used for the measurements to calculate the 
means and standard deviations. 
2.3.4 Cell culture and cell proliferation assay 
Human bone marrow-derived mesenchymal stem cells (hMSCs, passage 2) were purchased from 
LONZA (Walkersville MD, USA). The cells were cultured in 175 cm2 tissue culture flasks (BD Falcon, 
USA) with normal cell culture medium at 37 °C and 5% CO2 and passaged after reaching confluence. The 
passage 4 hMSCs were seeded in 24-well cell culture plates at a density of 0.5 × 104 cells/cm2 and were 
cultured at 37 °C and 5% CO2. The cell culture medium was DMEM supplemented with 10% FBS, 100 
U/mL penicillin and 100 μg/mL streptomycin. After culture for 6 h, the medium was changed. The hMSCs 
cultured in 24-well cell culture plate with 1 mL of fresh cell culture medium without NPs supplement in each 
well was designated as a negative control (NC). The hMSCs cultured in 24-well cell culture plate with 1 mL 
fresh cell culture medium supplemented with 10 mM β-glycerophosphate and 100 nM dexamethasone but 
without NPs in each well were designated as a positive control (PC). The hMSCs cultured in 24-well cell 
culture plate with 1 mL fresh cell culture medium supplemented with 10 mM β-glycerophosphate and NPs 
(BCP NPs or DEX@BCP NPs) at different concentrations (25, 100, 250 and 500 μg/mL) in each well were 
designated as experimental groups. For all the groups, the medium was changed every 3 days. 
The viability of hMSCs of different groups after culture for 1, 3 and 7 days was analysed by a WST-1 
assay. The cells were washed with PBS and 1 mL of WST-1 solution (100 μL of WST-1 stock solution 
diluted with 900 μL of complete medium) was added into each well. The cells were further cultured for 
another 3 h. Afterwards, the solution was transferred to 96-well plates (200 μL per well). The absorbance of 
each well was measured at 440 nm using a plate reader (Benchmark Plus, Bio-Rad, Hercules, CA, USA). 
Every four samples of each group were used for the measurement to calculate means and standard deviations. 
In addition, live/dead staining of hMSCs was conducted with a cell stain live/dead double staining kit to 
confirm the live and dead cells in all groups. The hMSCs cultured for 3 days were washed twice with warm 
PBS and incubated in serum-free DMEM medium containing calcein-AM and propidium iodide (PI) for 15 
min. An inverted fluorescence microscope (Olympus, Japan) was used to capture the live/dead images. 
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2.3.5 Alkaline phosphatase (ALP) staining and ALP activity assay 
ALP expression of the hMSCs in different groups after culture for 14 days was visualized by ALP 
staining. The cells were washed twice with PBS and subsequently fixed with 4% paraformaldehyde at room 
temperature for 10 min. The fixed cells were further washed twice with PBS and incubated with 0.1% 
naphthol AS-MX phosphate and 0.1% fast blue RR salt in 56 mM 2-amino-2-methyl-1,3-propanediol 
working solution (pH = 9.9) at room temperature for 10 min. After the working solution was discarded and 
and the plates were washed with PBS, the cells were observed using an optical microscope.  
ALP activity assay was carried out by using the Sensolyte® pNPP alkaline phosphatase assay kit 
(Anaspec, USA) according to the manufacturer’s instructions. After being cultured for 14 days, the cells in 
each well were washed twice with PBS, lysed with 0.2% Triton-X 100, scraped off the plates and collected 
into a microcentrifugation tube. After incubation at 4 °C for 10 min under agitation, the lysate was 
centrifuged at 2500× g for 10 min to collect the supernatant. The supernatant was incubated with 
p-nitrophenyl phosphate (pNPP) substrate solution and the color change was measured with a plate reader at 
a wavelength of 405 nm. A calibration curve was drawn by using ALP standard solution to determine the 
concentration of ALP in each well. The relative ALP amount was normalized by total protein amount 
analysed by a Pierce® BCA Protein Assay Kit. Every three wells of each sample were used for the 
measurements to calculate the means and standard deviations. 
2.3.6 Alizarin Red S (ARS) staining and calcium deposition assay 
After 21 days of culture, calcium deposition of the hMSCs in all groups was measured by ARS staining. 
The cells were washed twice with PBS, fixed with 4% paraformaldehyde at room temperature for 10 min and 
incubated with 0.1% Alizarin Red S solution at room temperature for 30 min. The stained cells were washed 
twice with PBS and observed using an optical microscope. For a quantitative calcium deposition assay, the 
stained cells were dried in air overnight and then eluted with 5% perchloric acid at room temperature for 20 
min. The solution in each well was transferred into a 96-well plate and the absorbance was recorded with a 
plate reader at 405 nm. The results were normalized by total protein amount. Every three wells of each 
sample were used for the measurements. 
2.3.7 Quantitative real-time polymerase chain reaction (PCR) 
To analyse gene expression of the osteogenic markers of the hMSCs in different groups after culture for 
21 days, the cells were washed twice with PBS and collected for RNA extraction with the RNAeasy Mini kit 
(Qiagen, Netherlands) according to the manufacturer’s instructions. A first stand cDNA synthesis kit was 
used to convert the obtained RNA to cDNA. Real-time PCR was performed on a 7500 Real-Time PCR 
system (Applied Biosystems, USA) according to previously reported protocol [33]. The expression level of 
GAPDH, a housekeeping gene, was used as an endogenous control. The relative expression level of each 
target gene was calculated by using 2-ΔΔCt formula and gene expression in negative control was used as a 
reference. The primers and probes used for real time PCR are listed in Table 1.1. 
2.3.8 Statistical analysis 
All data are presented as mean ± standard deviation (SD) with experiments repeated in triplicate (n = 3). 
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Statistical analysis was performed using One-way ANOVA to evaluate the significance of the experimental 
data. A difference was considered significant when the p-value was less than 0.05. The data indicated with (*) 
refers to p < 0.05 compared with the negative control; (△) refers to p < 0.05 compared with the positive 
control; (#) refers to p < 0.05 compared with BCP NPs.  
 
Table 1.1. The primers and probes for real-time PCR. 
mRNA Oligonucleotide 
18 S rRNA Hs99999901_s1 
GAPDH Hs99999905_m1 
ALP Forward 5’-GACCCTTGACCCCCACAAT-3’ 
Reverse 5’-GCTCGTACTGCATGTCCCCT-3’ 
Probe 5’-TGGACTACCTATTGGGTCTCTTCGAGCCA-3’ 
Runx2  Hs00231692_m1 
IBSP Forward 5’-TGCCTTGAGCCTGCTTCC-3’ 
Reverse 5’-GCAAAATTAAAGCAGTCTTCATTTTG-3’ 
Probe 5’-CTCCAGGACTGCCAGAGGAAGCAATCA-3’ 
BMP-2 Hs00154192_m1 
2.4 Results 
2.4.1 Synthesis and characterization of DEX-loaded BCP NPs 
The BCP NPs were prepared from calcium nitrate tetrahydrate solution and ammonium phosphate 
dibasic solution by liquid precipitation. DEX was introduced in the BCP NPs to prepare DEX-loaded BCP 
NPs (DEX/BCP NPs and DEX@BCP NPs). The DEX/BCP NPs were prepared by immersing BCP NPs in a 
DEX solution and DEX@BCP NPs were prepared by introducing DEX during the formation of BCP NPs. 
The BCP NPs and DEX@BCP NPs prepared with a DEX feeding amount of 4.5 mg were used for 
characterization. The BCP NPs and DEX@BCP NPs could be easily dispersed in water to form stable 
colloid suspension solution (Fig. 2.1a). The XRD spectra of the BCP NPs and DEX@BCP NPs showed that 
the diffraction peaks of HA and β-TCP phases were identified (Fig. 2.1b). Major peaks at 2θ = 25.9o, 31.8o, 
46.7o and 49.5o indicated hydroxyapatite (HA) lattice planes of (0 0 2), (2 1 1), (2 2 2) and (2 1 3), 
respectively. Peaks at 2θ = 28.0o, 33.6o and 53.2o indicated β-tricalcium phosphate (β-TCP) lattice planes of 
(2 1 4), (1 1 12) and (2 0 20), respectively. The XRD spectrum of DEX@BCP NPs was similar to that of 
DEX@BCP NPs except that the XRD spectrum of DEX@BCP NPs had some slightly higher level of noise, 
which should be due to the DEX incorporation. No detectable alterations in the broadness of the typical 
peaks related to HA and β-TCP lattice plane were observed after the DEX loading. The results showed that 
both BCP NPs and DEX@BCP NPs were composed of HA and β-TCP, indicating the biphasic components 
of calcium phosphate in the NPs. Incorporation of DEX did not affect the biphasic characteristics of BCP 
NPs. 
Dynamic light scattering (DLS) was used to measure the average hydrodynamic size of the BCP NPs 
and DEX@BCP NPs dispersed in water (Fig. 2.1c). The hydrodynamic size of the BCP NPs and DEX@BCP 
NPs was 895.0 ± 211.2 nm and 605.6 ± 191.0 nm, respectively. Furthermore, zeta potential was measured to 
confirm the surface charge of the prepared NPs (Fig. 2.1d). The zeta potential of the BCP NPs was -27.9 ± 
1.9 mV, while that of the DEX@BCP NPs was -22.6 ± 1.0 mV. Incorporation of DEX into the BCP NPs 
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decreased the zeta potential of the NPs.  
The BCP NPs and DEX@BCP NPs were observed by TEM to show the crystal morphology of BCP 
NPs before and after DEX loading. The BCP NPs had short rod-like morphology and agglomerated into 
needle-like crystals (Fig. 2.2a-b). The DEX@BCP NPs had similar size and morphology to those of the BCP 
NPs (Fig. 2.2c-d). The rod-like BCP NPs and DEX@BCP NPs had a size of 25-70 nm in length and 4-20 nm 
in width. The results indicated that loading of DEX did not affect the size and morphology of BCP NPs. The 
larger hydrodynamic sizes of the BCP NPs and DEX@BCP NPs than those measured from their TEM 
images should be due to agglomeration of the NPs in water. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1. Gross appearance photographs of aqueous solution of the BCP NPs and DEX@BCP NPs (a), X-ray 
diffraction (XRD) pattern (b), hydrodynamic size (c) and zeta potential (d) of the BCP NPs and DEX@BCP 
NPs. 
2.4.2 DEX loading and release profile of DEX-loaded BCP NPs 
The amount of DEX loaded in the DEX/BCP NPs and DEX@BCP NPs prepared with different initial 
feeding amount of DEX (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5 and 5.0 mg) was determined by using a 
UV-vis spectrophotometer (Fig. 2.3). For the DEX/BCP NPs prepared by method 1, the loading amount 
increased from 45.1 ± 11.0 ng/mg DEX/BCP NPs (DEX feeding amount: 0.5 mg) to 192.0 ± 11.3 ng/mg 
DEX/BCP NPs (DEX feeding amount: 4.0 mg) (Fig. 2.3a). When the feeding amount of DEX was 4.5 and 
5.0 mg, the loading amount was 186.8 ± 15.6 and 189.8 ± 17.3 ng/mg DEX/BCP NPs, respectively, which 
indicated the DEX loading amount reached saturation. With the increase of DEX feeding amount, the 
loading efficiency of DEX decreased from 22.9 ± 3.5 % to 9.6 ± 0.9 % (Fig. 2.3b).  
For the DEX@BCP NPs prepared by method 2, the DEX loading amount increased from 158.8 ± 14.3 
to 593.8 ± 19.8 ng/mg DEX@BCP NPs with the increasing of initial feeding amount of DEX from 0.5 to 4.5 
mg (Fig. 2.3a). When the initial feeding amount of DEX was 5.0 mg, the loading amount was 590.0 ± 19.2 
ng/mg, which was almost the same as the loading amount when the initial feeding amount of DEX was 4.5 
mg. The results indicated the loading amount reached saturation when the feeding amount of DEX was 
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higher than 4.5 mg. Increase of the initial feeding amount of DEX resulted in decreasing of loading 
efficiency from 80.7 ± 1.7 % to 30.0 ± 1.0 % (Fig. 2.3b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2. TEM images of the BCP NPs (a and b) and DEX@BCP NPs (c and d) at low (a, c) and high (b, d) 
magnifications. Scale bar: (a) and (c), 100 nm; (b) and (d), 20 nm. 
 
Based on the results of loading amount and loading efficiency, the DEX/BCP NPs and DEX@BCP NPs 
prepared with a feeding amount of 4.5 mg DEX were used for further release profile assay. The DEX/BCP 
NPs and DEX@BCP NPs showed different DEX release profiles (Fig. 2.3c and d). There was a rapid release 
of DEX during the first 3 d for both DEX/BCP NPs and DEX@BCP NPs. The accumulated DEX release 
percentage for the DEX/BCP NPs reached 82.6 ± 3.4% at day 3 and slightly increased in the following days. 
However, the accumulated DEX release percentage from the DEX@BCP NPs only reached 40.5 ± 3.9% at 
day 3 and a further sustained and controlled DEX release was observed over the 21-day period (Fig. 2.3d). 
The total amount of DEX released from the DEX/BCP NPs after 21 days was 176.2 ± 5.3 ng/mg DEX/BCP 
NPs, while that released from the DEX@BCP NPs after 21 d was 505.5 ± 19.1 ng/mg DEX@BCP NPs (Fig. 
2.3c). The percentage of released DEX for DEX/BCP NPs and DEX@BCP NPs after 21 days was 94.3 ± 
2.8 % and 85.1 ± 3.2 %, respectively (Fig. 2.3d). 
The loading amount and release profile results indicated that the DEX@BCP NPs prepared with a 
feeding amount of 4.5 mg DEX reached the highest loading amount of DEX and had a sustained release of 
DEX for a prolonged period. High loading of DEX and sustained release of DEX are important properties of 
carriers for drugs and growth factors. Therefore, from all the DEX-loading BCP NPs (DEX/BCP NPs and 
DEX@BCP NPs), only the DEX@BCP NPs prepared with a feeding amount of 4.5 mg DEX were used for 
other experiments including the previous characterization and the following cell culture. The BCP NPs 
without DEX incorporation was used as a counterpart.  
2.4.3 Cell culture and cell proliferation assay 
The viability and proliferation of hMSCs cultured with BCP NPs and DEX@BCP NPs prepared with a 
feeding amount of 4.5 mg DEX for 1, 3 and 7 days were assessed by using live/dead staining and WST-1 
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assay (Fig. 2.4). The hMSCs after incubation with the BCP NPs and DEX@BCP NPs at a concentration of 
25, 100, 250 and 500 μg/mL (denoted as BCP-25, BCP-100, BCP-250, BCP-500, DEX@BCP-25, 
DEX@BCP-100, DEX@BCP-250 and DEX@BCP-500, respectively) for 3 d were visualized by a live/dead 
staining (Fig. 2.4a). The cells showed well spreading morphology. No dead cells (red color) were observed 
in any of the groups. All the cells cultured with BCP NPs and DEX@BCP NPs and the control groups 
showed high viability. The results indicated the BCP NPs and DEX@BCP NPs at the studied concentrations 
did not affect cell viability.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.3. Relation of DEX loading amount (a) and DEX loading efficiency (b) of the DEX/BCP NPs and 
DEX@BCP NPs with different initial feeding amount of DEX. Cumulative amount (c) and percentage (d) of 
released DEX from the DEX/BCP NPs and DEX@BCP NPs prepared with a feeding amount of 4.5 mg 
DEX. Data represent means ± SD, N=3. 
 
WST-1 assay results showed that the cell viability of hMSCs after being cultured with the BCP NPs and 
DEX@BCP NPs for 1 day had no significant difference as compared to the negative and positive controls 
(Fig. 2.4b). The cells cultured with the BCP NPs and DEX@BCP NPs and control groups proliferated with 
increase of culture time. After culture for 3 days, the DEX@BCP NPs did not show evident influence on cell 
viability even at a high concentration of 500 μg/mL. After culture for 7 days, proliferation of hMSCs 
cultured with the BCP NPs was slightly higher than that of the negative control. Proliferation of hMSCs 
cultured with the DEX@BCP-25, DEX@BCP-100 and DEX@BCP-250 was slightly higher than that of the 
positive control, while the proliferation of hMSCs cultured with the DEX@BCP-500 was slightly lower than 
that of the positive control.  
2.4.4 ALP staining and ALP activity assay 
ALP is generally considered as an early stage marker of osteogenic differentiation [34]. The ALP 
staining and ALP activity assay were performed to investigate the osteogenic differentiation activity of 
hMSCs after 14 days of culture (Fig. 2.5). ALP staining demonstrated that slightly more intense staining was 
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observed in the cells cultured with the BCP-100, BCP-250 and BCP-500 NPs than that of the negative 
control group (Fig. 2.5a). Each concentration of DEX@BCP NPs showed higher degree of ALP staining than 
that of the BCP NPs. Meanwhile, when compared to the positive control, the cells cultured with the 
DEX@BCP NPs displayed a concentration-dependent increase of ALP staining level. ALP activity assay 
showed the cells cultured with the BCP-250, BCP-500, DEX@BCP-25, DEX@BCP-100, DEX@BCP-250 
and DEX@BCP-500 had significantly higher ALP amount than did the negative control. For each 
concentration, DEX@BCP NPs showed significantly higher ALP amount than did the cells cultured with the 
BCP NPs. The ALP amount in the cells cultured with the DEX@BCP-250 and DEX@BCP-500 was higher 
than that of the positive control. The results indicated that ALP activity in hMSCs was promoted by the 
DEX@BCP NPs in a concentration-dependent manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.4. Live/dead staining of hMSCs after culture with the BCP NPs and DEX@BCP NPs for 3 days (a) 
and proliferation of hMSCs after culture with the BCP NPs and DEX@BCP NPs for 1, 3 and 7 days (b). The 
DEX@BCP NPs prepared with a feeding amount of 4.5 mg DEX were used. The NPs concentrations were 
25, 100, 250 and 500 μg/mL. NC and PC are negative and positive controls, respectively. Scale bar: 100 μm. 
Data represent means ± SD, N=3. 
2.4.5 ARS staining and calcium deposition assay 
To confirm bone matrix maturation and mineralization, calcium deposition was evaluated after hMSCs 
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were cultured with each concentration of the BCP NPs and DEX@BCP NPs for 21 days (Fig. 2.6).  All of 
the experimental groups except BCP-25 group were positively stained. The ARS staining became thicker and 
denser with the increase of the BCP NPs and DEX@BCP NPs concentration. At the same concentration, the 
cells cultured with the DEX@BCP NPs were more strongly stained than the cells cultured with the BCP NPs. 
A quantitative analysis of ARS staining was performed by eluting ARS from the stained cells (Fig. 2.6b). 
Compared to cells cultured with the BCP NPs, the cells cultured with the DEX@BCP NPs displayed a 
significant increase in the calcium deposition. There was no significant difference between the cells cultured 
with the DEX@BCP-25 and the positive control. However, calcium deposition of the cells cultured with the 
DEX@BCP-100, DEX@BCP-250 and DEX@BCP-500 was significantly higher than that of the positive 
group, which showed an increasing trend in a concentration-dependent manner.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.5. ALP staining (a) and ALP activity assay (b) of hMSCs after culture with the BCP NPs and 
DEX@BCP NPs at a concentration of 25, 100, 250 and 500 μg/mL for 14 days. The DEX@BCP NPs 
prepared with a feeding amount of 4.5 mg DEX were used. Scale bar: 500 μm. Data represent means ± 
SD, N=3.  (*) refers to p < 0.05 compared with negative control; (△) refers to p < 0.05 compared with 
positive control; (#) refers to p < 0.05 compared with BCP NPs. 
2.4.6 Gene expression analysis 
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   The expression of osteogenic marker genes such as ALP, runt-related transcription factor 2 (Runx2), 
bone sialoprotein 2 (IBSP) and bone morphogenetic protein-2 (BMP-2) in hMSCs were analysed by 
quantitative real-time PCR after 21 days of culture (Fig. 2.7). The results showed that both BCP NPs and 
DEX@BCP NPs up-regulated the gene expression of ALP, Runx2, IBSP and BMP-2 when compared to the 
negative control. The expression of these genes in the cells cultured with the DEX@BCP NPs was 
significantly higher than that of the cells cultured with the BCP NPs at the same concentrations. When 
compared to the positive control, ALP and IBSP genes were significantly up-regulated by the 
DEX@BCP-250 and DEX@BCP-500 (Fig. 2.7a and 2.7c). Runx2 gene was significantly up-regulated by the 
DEX@BCP-100, DEX@BCP-250 and DEX@BCP-500 (Fig. 2.7b). BMP-2 gene was significantly 
up-regulated by the DEX@BCP-250 (Fig. 2.7d). The results suggested that the DEX@BCP NPs stimulated 
gene expression of the osteogenic markers in hMSCs in a concentration-dependent manner. DEX@BCP NPs 
at a higher concentration resulted in higher expressions of osteogenic marker genes. The gene expression 
results were in good agreement with the ALP activity and calcium deposition assay results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.6. ARS staining (a) and calcium deposition assay (b) of hMSCs after culture with the BCP NPs and 
DEX@BCP NPs at a concentration of 25, 100, 250 and 500 μg/mL for 21 days. The DEX@BCP NPs 
prepared with a feeding amount of 4.5 mg DEX were used. Scale bar: 200 µm. Data represent means ± 
SD, N=3.  (*) refers to p < 0.05 compared with negative control; (△) refers to p < 0.05 compared with 
positive control; (#) refers to p < 0.05 compared with BCP NPs. 
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2.5 Discussion 
DEX is an osteogenic inducer for stem cells which is widely used in bone tissue engineering [35, 36]. It 
plays a key role in controlling regulation of genes and cellular processes essential for cellular growth and 
differentiation [37]. Combination of DEX with a biomaterial carrier should maximize the therapeutic effect 
of DEX. On the other hand, the main inorganic component of natural bone, CaP NPs, has been frequently 
used as a carrier for drugs, proteins, DNA and RNA for the skeletal or other systems [9, 38, 39]. Because 
formation of CaP NPs is a straightforward precipitation reaction, incorporation of other molecules or drugs 
only requires the molecules or drugs of interest be present during the CaP formation process [23, 25, 40]. 
CaP has different phases including hydroxyapatite (HA), tricalcium phosphate (TCP), octacalcium phosphate 
(OCP), dicalcium phosphate dehydrate (DCPD) and so on [41, 42]. Among them, HA and β-TCP are two 
important CaP biomaterials used in bone repair. HA has high strength but poor degradability, while β-TCP 
has good degradability but low strength. Combination of HA and β-TCP to prepare biphasic calcium 
phosphate (BCP) has been proposed and shown great clinical potential [22, 43-45]. In present study, BCP 
NPs were prepared as DEX carrier because of their osteoconductive properties and desirable characteristics 
as a bone graft biomaterial. The DEX-loaded BCP NPs were prepared by immersion BCP NPs into DEX 
aqueous solution (DEX/BCP NPs) or DEX incorporation during BCP NPs precipitation (DEX@BCP NPs). 
The biphasic characteristic of the BCP NPs and DEX@BCP NPs was demonstrated by the XRD analysis 
(Fig. 2.1b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.7. Expression of ALP (a), Runx2 (b), IBSP (c) and BMP-2 (d) of hMSCs after culture with the BCP 
NPs and DEX@BCP NPs at a concentration of 25, 100, 250 and 500 μg/mL for 21 d. Data represent means ± 
SD, N=3. (*) refers to p < 0.05 compared with negative control; (△) refers to p < 0.05 compared with 
positive control; (#) refers to p < 0.05 compared with BCP NPs. 
 
The prepared BCP NPs and DEX@BCP NPs had short rod-like shape and agglomerated in water as 
shown in Fig. 2.2. The agglomeration of CaP NPs should be due to the electrostatic interaction of calcium 
and phosphate ions on the surface of CaP NPs [46, 47]. Incorporation of DEX during BCP precipitation 
resulted in similar crystal morphology while a slightly smaller hydrodynamic size and lower zeta potential 
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(Fig. 2.1c). The decrease of hydrodynamic size and zeta potential of the DEX@BCP NPs should be due to 
the shielding effect of DEX. In the preparation of DEX@BCP NPs, OH groups in DEX might 
electrostatically interact with the calcium ions and then resulted in encapsulation of DEX in the DEX@BCP 
NPs. DEX molecules might partially affect the electrostatic interaction between calcium and phosphate ions 
of the DEX@BCP NPs, thus reducing the agglomeration of DEX@BCP NPs. Some bone matrix proteins, 
bovine serum albumin and amylase have been also reported to retard CaP crystal growth when present 
during precipitation of CaP [48-50]. 
The DEX@BCP NPs showed higher loading amount and loading efficiency than the DEX/BCP NPs 
(Fig. 2.1a and b). DEX could be adsorbed only on the surface of the BCP NPs when the DEX/BCP NPs were 
prepared. In contrast, DEX could be not only adsorbed on the surface of BCP NPs but also encapsulated in 
the BCP NPs during the liquid precipitation when the DEX@BCP NPs were prepared. The double effects of 
surface adsorption and encapsulation should increase the loading amount and efficiency of DEX in the 
DEX@BCP NPs. 
The DEX/BCP NPs and DEX@BCP NPs showed different DEX release profiles (Fig. 2.3c and d). The 
DEX/BCP NPs and DEX@BCP NPs both revealed rapid DEX release during the first 3 days. 82.6 ± 3.4% of 
the loaded DEX in the DEX/BCP NPs and 40.5 ± 3.9% of the loaded DEX in the DEX@BCP NPs was 
released during the first 3 days. The rapid release of DEX in the first 3 days should be due to the adsorbed 
DEX. Therefore, most of the loaded DEX was released from the adsorption type loading model (DEX/BCP 
NPs). Because DEX was both adsorbed and encapsulated in the DEX@BCP NPs, the DEX@BCP NPs 
showed a sustained and controlled release of DEX. Many studies have used CaP particles as drug carriers 
just by coating the drugs onto the surface of CaP particles [51-53]. However, a rapid initial burst release of 
drugs is accompanied with these drug-loaded CaP particles and the drugs release cannot last as long as 
needed [54-57]. The DEX@BCP NPs should meet the prolonged period release requirement because the 
DEX release could last more than 21 days. 
The DEX@BCP NPs at different concentrations (25, 100, 250 and 500 μg/mL) maintained high cell 
viability and promoted proliferation of hMSCs. The control BCP NPs also showed a promotive effect on 
proliferation of hMSCs, which should be due to the locally released Ca 2+ and PO43- [58], After 7 days 
culture, the proliferation of hMSCs cultured with the DEX@BCP NPs was lower than that cultured with the 
BCP NPs. This should be due to the osteogenic differentiation of hMSCs cultured with the DEX@BCP NPs. 
It has been reported that proliferation of the hMSCs was retarded when DEX was used to stimulate the 
differentiation of hMSCs [59, 60].  
The ALP activity assay, Ca deposition and gene expression results indicated that the DEX@BCP NPs 
promoted osteogenic differentiation of hMSCs. The promotive capacity of the DEX@BCP NPs should be 
the synergistic effects of the BCP NPs and DEX. Numerous studies have reported that various types of CaPs 
including BCP can not only induce the ectopic bone formation in vivo, but also promote the osteogenic 
differentiation of MSCs in vitro, due to the increased local concentrations of calcium and phosphate ions [43, 
61, 62]. In this study, DEX was released from the DEX@BCP NPs in a sustainable manner and the released 
DEX could effectively maintain the concentration to stimulate the osteogenic differentiation of hMSCs. At 
day 3, the amount of released DEX was 240.5 ± 23.4 ng/mg DEX@BCP NPs that was 40.5 ± 3.9 % of the 
total loaded amount. Based on the released data, the released DEX concentration in the culture medium was 
calculated to be about 24 ng/mL for the DEX@BCP-100 group, 60 ng/mL for the DEX@BCP-250 group 
and 120 ng/mL for the DEX@BCP-500 group. DEX concentration in positive control group was 39.6 ng/mL. 
Given that the maximal stimulation effect of DEX on osteoblast differentiation is 10−8 to 10−6 M (3.96 
ng/mL to 396 ng/mL) [63-65], all the three groups (DEX@BCP-100, DEX@BCP-250, and DEX@BCP-500) 
presented the proper concentration for triggering osteogenic differentiation of hMSCs. The increase of 
DEX@BCP NPs concentrations resulted in the increasing amount of the released DEX, as well as the local 
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concentration of calcium and phosphate ions. The DEX@BCP NPs combined the advantages of both BCP 
NPs and DEX. They should be useful for osteogenic differentiation of stem cells and bone tissue 
engineering. 
2.6 Conclusions 
Biphasic calcium phosphate nanoparticles (BCP NPs) were prepared as the DEX carrier. DEX was 
incorporated in the BCP NPs by immersion of BCP NPs in a DEX solution or addition of DEX in the 
reaction solution during BCP NPs formation. The DEX@BCP NPs prepared by the second method showed a 
higher DEX loading amount and loading efficiency than did the DEX/BCP NPs prepared by the first method. 
Incorporation of DEX did not change the biphasic characteristics of BCP NPs. The DEX@BCP NPs had a 
more sustainable and longer release of DEX than did the DEX/BCP NPs. The DEX@BCP NPs maintained 
high cell viability and promoted proliferation of hMSCs. The hMSCs cultured with the DEX@BCP NPs 
showed high ALP activity, positive calcium deposition and up-regulated expression of osteogenic marker 
genes. The DEX@BCP NPs could release DEX in a sustained way and enhance osteogenic differentiation of 
hMSCs. The results should provide useful information for the preparation of DEX-loaded systems for bone 
tissue engineering. 
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Preparation of dexamethasone-loaded biphasic calcium phosphate 
nanoparticles/collagen porous composite scaffolds for bone tissue 
engineering 
 
 
 
 
3.1 Summary 
As an attractive strategy, bone tissue engineering (bone TE) has been widely investigated to repair bone 
defects. However, the rapid and effective bone regeneration of large non-healing defects is still a great 
challenge. Multifunctional scaffolds having osteoinductivity and osteoconductivity are desirable to fasten 
functional bone tissue regeneration. In this part, composite scaffolds of collagen and biphasic calcium 
phosphate nanoparticles (BCP NPs) with a controlled and sustained release nature of DEX and controlled 
pore structures were prepared for bone tissue engineering. DEX was introduced in BCP NPs during 
preparation of BCP NPs and then the DEX-loaded NPs were hybridized with collagen scaffolds, which pore 
structures were controlled by using pre-prepared ice particulates as a porogen material. The composite 
scaffolds had well controlled and interconnected pore structures, high mechanical strength and sustained 
release of DEX. The composite scaffolds showed good biocompatibility and promoted osteogenic 
differentiation of hMSCs when used for three-dimensional culture of hMSCs. Subcutaneous implantation of 
the DEX@BCP/Col composite scaffolds at the dorsa of athymic nude mice demonstrated that the composite 
scaffolds facilitated ectopic bone tissue regeneration. The results indicated the DEX@BCP/Col composite 
scaffolds had high potential for bone tissue engineering. 
3.2 Introduction 
Nowadays, autografts and allografts are the most common solutions for repair of large-sized bone 
defects. Nevertheless, they have some drawbacks such as the limited sources, extra invasive surgery and 
immunological rejection [1]. Therefore, more and more attention has been drawn to bone tissue engineering 
(bone TE). Bone TE is a strategy combining biotechnology and biomaterials to induce new bone 
regeneration, which is a complex and dynamic process that starts with cell migration and adhesion followed 
by cell proliferation, differentiation, matrix formation along with remodeling of bone [2]. Scaffolds have 
been used for bone TE to control cell functions and keep regeneration spaces. Besides good biocompatibility 
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and biodegradability, scaffolds used for bone TE should have excellent osteoconductivity, osteoinductivity, 
interconnected porous structure and high mechanical property [3-5]. Osteoconductivity can ensure migration, 
adhesion and survival of osteogenic cells. Osteoinductivity can induce osteogenic differentiation of stem 
cells [6].  
Many efforts have been made to prepare scaffolds for bone TE. To mimic the extracellular matrix 
composition of bone, a variety of strategies have been considered, including usage of the components present 
in natural bone [7], controlling of pore structure and interconnectivity [8], construction of multiple scale 
architectures [9] and incorporation of growth factors [10]. For example, calcium phosphate (CaP) has been 
hybridized with polymers in the forms of tablets [11], blends [12], pastes [13] or cements [14]. However, 
these CaP/polymer composite scaffolds do not have appropriate pore structures for cell accommodation and 
migration. In particular, their pore interconnectivity is poor [15-17]. 
To render scaffolds with good osteoinductivity, growth factors have been incorporated in the scaffolds. 
Nevertheless, the most commonly used growth factors such as bone morphogenetic proteins (BMPs) and 
transforming growth factor beta (TGF-β) are proteins and can easily lose their bioactivity during the 
preparation procedures [18]. To minimize denaturation and maintain their bioactivity, growth factors are 
generally introduced in scaffolds by physical adsorption. The release of physically adsorbed proteins always 
exhibits an initial burst and cannot last for a long period [19-24]. On the other hand, dexamethasone (DEX), 
as a low molecular weight osteoinductive factor, has drawn much attention for incorporation in scaffolds for 
bone TE because of its high stability even in tough chemical environment [25]. DEX and hydroxyapatite 
nanoparticles have been hybridized with gelatin and poly(L-lactide) to construct 
hydroxyapatite/DEX/PLLA/gelatin composite scaffold by electrospinning technique [26]. DEX-loaded 
mesoporous silica nanoparticles have been deposited onto poly(L-lactic acid)/poly(ε–caprolactone) 
nanofibrous scaffold by electrophoretic deposition [27]. A dual delivery system of BMP-2 and DEX has been 
designed by co-electrospinning the blending solution that is composed of BMP-2-encapsulated bovine serum 
albumin nanoparticles, DEX and poly(ε-caprolactone)-co-poly(ethylene glycol) (PCE) copolymer [28]. 
These composite scaffolds have shown the synergistic effects of the released osteogenic factors. However, 
the problems of initial burst release and a short release period of DEX need to be solved. Furthermore, 
simultaneous release of both DEX and calcium and phosphorus ions is desirable for synergistic promotion of 
new bone regeneration. 
In this study, composite scaffolds of collagen and DEX-loaded biphasic CaP nanoparticles (BCP NPs) 
were prepared for a sustainable release of DEX together with the calcium and phosphorous ions. DEX was 
incorporated in the BCP NPs during their preparation to allow the DEX being physically locked in the 
crystals of BCP NPs for a sustainable and simultaneous release profile of DEX, calcium and phosphorous 
ions. The microporous structure of the composite scaffolds was controlled by using pre-prepared ice 
particulates as a porogen material. The composite scaffolds were used for three-dimensional culture of 
human bone marrow-derived mesenchymal stem cells (hMSCs). Their effects on proliferation and osteogenic 
differentiation of hMSCs were compared with collagen scaffold and BCP NPs/collagen composite scaffold. 
Subcutaneous implantation of the composite scaffolds at the dorsa of athymic nude mice was used to 
demonstrate their promotive effects on ectopic bone tissue regeneration. 
3.3  Materials and methods 
3.3.1 Preparation of BCP NPs and DEX@BCP NPs  
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Biphasic calcium phosphate nanoparticles (BCP NPs) were prepared by adding dropwise 75.0 mL of 0.5 
M calcium nitrate tetrahydrate (Ca(NO3)2·4H2O, Sigma-Aldrich, USA) solution to 50 mL of 0.5 M 
ammonium phosphate dibasic ((NH4)2HPO4, Sigma-Aldrich, USA)) solution by a syringe pump (KD 
Scientific Inc., USA) [29]. After reacting at 55 °C and a pH of 9.5 for 30 minutes under stirring (700 rpm), 
the slurry was aged for 36 hours at room temperature to form stable BCP NPs. DEX-loaded BCP NPs 
(denoted as DEX@BCP NPs) were prepared by adding dropwise the mixture solution of DEX and 
Ca(NO3)2·4H2O (75.0 mL) to 50 mL of 0.5 M (NH4)2HPO4 solution. The mixture solution of DEX and 
Ca(NO3)2·4H2O was prepared by adding 3 mL of 0.75, 1.50 and 2.25 mg/mL of DEX in ethanol to 72.0 mL 
of 0.52 M Ca(NO3)2·4H2O solution. The reaction was continued in a 55 °C water bath for 30 minutes under 
stirring and then aged for 36 hours at room temperature to obtain stable DEX@BCP NPs. The DEX@BCP 
NPs prepared at the three different DEX feeding concentrations were denoted as DEX1@BCP NPs, 
DEX2@BCP NPs and DEX3@BCP NPs, respectively. The prepared DEX@BCP NPs were dispersed in 20 
mL ethanol and shaken at 200 rpm and room temperature for 20 minutes followed with centrifugation at 
8000 rpm. The washing with ethanol was repeated for 3 times to remove the DEX adsorbed on the surface of 
the DEX@BCP NPs.  
3.3.2 Preparation of DEX@BCP NPs/collagen composite scaffolds 
A 2.5% (w/v) solution of collagen was prepared by dissolving porcine type I collagen (Nitta Gelatin, 
Japan) in a 10% (v/v) ethanol aqueous solution. Ice particulates were prepared by spaying pure water in 
liquid nitrogen and ice particulates with the diameters between 425 and 500 μm were obtained by sieving the 
ice particulates through two sieves having a respective mesh size of 425 and 500 μm [30]. The BCP NPs, 
DEX1@BCP NPs, DEX2@BCP NPs and DEX3@BCP NPs were individually dispersed in a 10% (v/v) 
ethanol aqueous solution to prepare their respective dispersion solution. The collagen solution, NPs 
dispersion solution and ice particulates were kept in a -5 °C low temperature chamber (Espec, Osaka, Japan) 
for 2 hours to balance their temperature to -5 °C.  
To optimize the mass ratio of NPs and collagen in the composite scaffolds, a series of porous 
BCP/collagen (BCP/Col) composite scaffolds with a different mass ratio of BCP NPs/collagen were prepared. 
At first, 3 mL of the pre-cooled BCP NPs suspension solution at a concentration of 187, 140, 112 and 93 
mg/mL was added dropwise to 11 mL of the pre-cooled collagen solution (2.5% (w/v)) at -5 °C and mixed 
well. The final concentration of collagen in the collagen/BCP NPs suspension solution was 2.0% (w/v). The 
mass ratio of the BCP NPs/collagen was 2: 1, 1.5: 1, 1.2: 1 and 1: 1 (w/w), respectively. Subsequently, the 
temperature-balanced ice particulates were added to the collagen/BCP NPs suspension solution at a ratio of 
50: 50 (w/v) at -5 °C. The components were mixed carefully to allow the ice particulates being 
homogeneously distributed in the collagen/BCP NPs suspension solution without air bubble generation and 
then poured into silicone frames which were placed on PFA film-wrapped copper plates. The entire 
constructs were placed at -12 °C for 12 hours to slowly freeze the mixture solution and then frozen at -80 °C 
for 6 hours. Finally, the frozen constructs were freeze-dried for 2 days in a Wizard 2.0 freeze dryer (VirTis, 
Gardiner, NY). The freeze-dried constructs were cross-linked with 50 mM 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, Peptide Institute, Inc.) and 20 mM 
N-hydroxysuccimide (NHS, Wako Pure Chemical Industries, Ltd.) in an 80% (v/v) ethanol aqueous solution 
at room temperature under gentle shaking (~ 20 rpm) for 8 hours. After cross-linking, the BCP/Col 
composite scaffolds were washed 3 times with Milli-Q water and immersed in a 0.1 M glycine aqueous 
solution to block unreacted NHS residues. The BCP/Col composite scaffolds were washed with water for 6 
times and freeze-dried for usage of the following experiments.  
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After preparation of the serial BCP/Col composite scaffolds, the pore structure and mechanical property 
were measured to determine the optimal mass ratio of BCP NPs/collagen in the scaffold. The optimized mass 
ratio of BCP NPs/collagen was 1: 1 and used for fabrication of the DEX@BCP NPs/collagen 
(DEX@BCP/Col) composite scaffolds. The preparation procedure of DEX1@BCP NPs/collagen 
(DEX1@BCP/Col), DEX2@BCP NPs/collagen (DEX2@BCP/Col) and DEX3@BCP NPs/collagen 
(DEX3@BCP/Col) composite scaffolds was the same as that of BCP/Col composite scaffolds described 
above by changing the BCP NPs to DEX1@BCP NPs, DEX2@BCP NPs and DEX3@BCP NPs, respectively. 
Control collagen (Col) scaffold was prepared by the same procedure as that of the BCP/Col composite 
scaffolds by using 2.0% (w/v) collagen solution without addition of any NPs.  
3.3.3 Characterization of NPs and scaffolds 
A JEOL 2100F transmission electron microscope (TEM, JEOL, Japan) was used to visualize the 
morphology of the NPs. An aqueous solution containing 10 μL of NPs was dropped on a carbon-coated 
copper grid to prepare the samples for TEM. The elemental mapping of the NPs was obtained on a 
field-emission electron microscope (JEM-2100F, JEOL, Japan). The pore structures of the Col, BCP/Col, 
DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col scaffolds were observed with a scanning electron 
microscope (SEM, S-4800, Hitachi, Japan). The cross-sections of the scaffolds were coated with platinum by 
a sputter coater (E-1030, Hitachi, Japan) before observation. The pore size was analyzed by measuring the 
diameters of pores (≥40 pores per image) from four SEM images of each type of scaffolds with an ImageJ 
software (ImageJ2, NIH, USA). The mechanical property of the scaffolds was measured by a static 
compression mechanical test machine (TA. XTPlus, Texture Technologies Corp., USA). The scaffolds were 
punched into cylindrical discs (Φ6 mm × H3 mm). The cylindrical discs were hydrated by degassing the 
discs in phosphate buffered saline (PBS) and soaked in PBS for 2 hours before testing. Each sample was 
compressed at a rate of 0.1 mm/s to generate stress-strain curves. The Young’s modulus was calculated from 
the initial linear region of the stress-strain curves. 3 samples were tested for each type of the scaffolds. The 
porosity of the scaffolds was calculated according to Archimedes’ principle by the following formula: 
porosity = Vpore/V = ((W2－W1)/ρ/V) × 100%, where Vpore is the volume of the pore, V is the total volume of 
the scaffold, W1 is the dry weight of the scaffold, W2 is the weight of the scaffold with water and ρ is the 
density of water [30]. 3 samples of each scaffold were used for the measurement to calculate the mean and 
standard deviation.  
3.3.4 DEX release from DEX@BCP/Col composite scaffolds 
The DEX release experiment of the DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col 
composite scaffolds was performed in a PBS solution (pH 7.4). The scaffolds were punched into cylindrical 
discs (Φ6 mm × H3 mm). Every 2 discs were immersed in 2 mL of PBS and gently shaken (60 rpm) at 37 °C. 
The released amount of DEX was measured at 242 nm by a UV-vis spectrophotometer after incubation for 
0.5, 1, 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31 and 35 days. To measure the total loading amount of DEX in the 
DEX@BCP/Col composite scaffolds, every 2 discs of the scaffolds were dissolved in 2 mL of a 6 M 
hydrochloric acid (HCl, Wako, Japan) solution for 3 hours. And then the mixture solution was centrifuged at 
8000 rpm for 10 minutes. The supernatant was taken out to measure the amount of DEX. The percentage of 
the DEX released from each type of the DEX@BCP/Col composite scaffolds was determined by dividing the 
release amount by the total loading amount of DEX. Each experiment was carried out in triplicate.   
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3.3.5 In vitro cell culture  
The Col, BCP/Col and DEX@BCP/Col scaffolds were punched into cylindrical samples (Φ6 mm × H3 
mm) and sterilized with ethylene oxide gas for 5 hours. The sterilized samples were conditioned in 
Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich, USA) at 37 °C for 4 hours. Human 
mesenchymal stem cells (hMSCs, passage 2) were purchased (Lonza, USA) and sub-cultured in MSCBM 
medium (Lonza, Swiss). The sub-cultured hMSCs at passage 4 were harvested by treatment with a 
trypsin/EDTA solution after reaching confluence. The harvested hMSCs were re-suspended in DMEM to 
prepare a cell suspension solution of 2 × 106 cells/mL for cell seeding. 85 μL of the cell suspension solution 
was dropped on the top side of the scaffold discs. After being cultured for 3 hours, the scaffold discs were 
turned upside down and another 85 μL of the cell suspension solution was dropped on another side of the 
scaffold discs. The total cell number seeded to each scaffold was 3.4 × 105. The cells/scaffold constructs 
were divided into seven groups: Col scaffold (Col), Col scaffold with additional free DEX in medium 
(Col+DEX), BCP/Col scaffold (BCP/Col), BCP/Col scaffold with additional free DEX in medium 
(BCP/Col+DEX), DEX@BCP/Col scaffolds with three different DEX loading amount (DEX1@BCP/Col, 
DEX2@BCP/Col and DEX3@BCP/Col). The Col, BCP/Col, DEX1@BCP/Col, DEX2@BCP/Col and 
DEX3@BCP/Col groups were cultured in DMEM supplemented with 10 mM β-glycerophosphate (2 mL 
medium per scaffold). The Col+DEX and BCP/Col+DEX groups were cultured in DMEM supplemented 
with 100 nM DEX and 10 mM β-glycerophosphate (2 mL medium per scaffold). The Col and BCP/Col were 
used as negative controls, while the Col+DEX and BCP/Col+DEX were used as positive controls. All groups 
were cultured under an atmosphere of 5% CO2 at 37 °C with a shaking speed of 60 rpm. Medium was 
changed every 3 days with the addition of fresh 100 nM DEX or 10 mM β-glycerophosphate.    
3.3.6 Analysis of cell attachment, distribution, viability and proliferation 
Cell attachment and distribution were analyzed by SEM observation and cell nucleus staining. For SEM 
observation, the samples were washed with PBS for 3 times and fixed with 2.5% glutaraldehyde at room 
temperature for 1 hour after being cultured for 1 day. After being washed with PBS and water each for 3 
times, the fixed samples were freeze-dried and their cross-sections were observed by SEM. For nucleus 
staining, the samples cultured for 1 day were washed with PBS for 3 times and fixed in 10% neutral buffered 
formalin for 24 hours. The fixed samples were dehydrated, embedded in paraffin and sectioned to get the 
vertical cross sections at a thickness of 7 μm. The cross-sections were de-paraffinized and the cell nuclei 
were stained with 2 μg/ml 4',6-diamidino-2-phenylindole dihydrochloride (DAPI, Dojindo, Japan). The 
stained cross-sections were observed with a fluorescence microscope (Olympus, Japan).  
Live/dead staining was performed to evaluate cell viability by using calcein-AM and propidium iodide 
staining reagents (Cellstain Double Staining Kit, Dojindo, Japan). After being cultured for 7 days, the 
samples were washed twice with warm PBS and incubated in serum-free DMEM medium containing 
calcein-AM and propidium iodide for 15 minutes. The stained samples were observed with an inverted 
fluorescence microscope (Olympus, Japan) to capture the live/dead cell images.  
Cell proliferation was investigated by measuring DNA amount in each sample after 1, 7, 14 and 28 days 
of culture. The samples were washed 3 times with water, freeze-dried for 48 hours and digested with a 
papain solution (400 μg/mL) containing 5 mM EDTA and 5 mM L-cysteine in 0.1 M phosphate buffer at a 
pH of 6.0. An aliquot of the papain digests was used for quantification of DNA content with Hoechst 33258 
dye (Sigma-Aldrich, USA) by a fluorescence spectrometer (FP8500, JASCO, Japan). At each time point, 
every 4 samples of each type of cells/scaffold constructs were used for the measurement. 
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3.3.7 ALP staining and ALP activity assay 
Alkaline phosphatase (ALP) staining and ALP activity assay were conducted after the cells/scaffold 
constructs were cultured for 14 days. The samples were washed with PBS for 3 times and then fixed with 4% 
paraformaldehyde for 10 minutes at room temperature. The fixed samples were washed with PBS for 2 times 
and incubated in a 56 mM 2-amino-2-methyl-1,3-propanediol aqueous solution (pH = 9.9) containing 0.1% 
fast blue RR salt and 0.1% naphthol AS-MX phosphate for 10 minutes at room temperature. After being 
washed with PBS for 3 times, the stained samples were sectioned by a blade to prepare vertical 
cross-sections. The cross-sections were observed with an optical microscope.  
A Sensolyte® pNPP alkaline phosphatase assay kit (Anaspec, USA) was used to analyze the ALP 
activity according to manufacturer’s instruction. The samples cultured for 14 days were washed with PBS for 
3 times, immersed into liquid nitrogen and then crushed into powder by an electric crusher. The powder was 
collected into a micro-centrifugation tube and 0.2% Triton X-100 was added to lyse the cells. After stirring 
for 10 minutes at 4 °C, the lysate was centrifuged for 10 minutes at 2500× g for collection of the supernatant. 
And then the supernatant was incubated with a p-nitrophenyl phosphate (pNPP) substrate solution followed 
by colorimetric detection at 405 nm. By using an ALP standard solution, a calibration curve was obtained. 
The DNA content in each sample after 14 days of culture was used to normalize the ALP amount. Each 
experiment was carried out in triplicate. 
3.3.8 PCR assay of in vitro samples 
The expression of osteogenesis-related genes encoding ALP, runt-related transcription factor-2 
(RUNX2), bone sialoprotein 2 (IBSP) and bone morphogenetic protein-2 (BMP-2) in the cells/scaffold 
constructs was analyzed by real-time PCR (RT-PCR). After 28 days of in vitro culture, the samples were 
washed with PBS for 3 times and frozen in liquid nitrogen. The frozen samples were crushed into powder 
and dissolved in Sepasol solution (Nacalai Tesque, Japan) to isolate RNA from the cells. For conversion of 
the RNA to cDNA, a first stand cDNA synthesis kit (Applied Biosystems, USA) was used. A 7500 
Real-Time PCR system (Applied Biosystems, USA) was used to perform the RT-PCR [31]. Expression of 
GAPDH (a housekeeping gene) was used as an endogenous control. The relative gene expression was 
calculated by using the 2-ΔΔCt method. The gene expression of cells in the Col group was used as a reference. 
Each experiment was carried out in triplicate. The primers and probes are listed in Table 1. 
3.3.9 In vivo implantation  
All the animal experiment procedures were approved by the Animal Experiments Committee of the 
National Institute for Materials Science and the experiment was conducted according to the committee 
guidelines. For in vivo implantation, the cells/scaffold constructs were prepared under the same condition as 
those used for in vitro cell culture. After 1 week of in vitro culture, the samples were subcutaneously 
implanted in the back of the 6 weeks old athymic nude mice. Every mouse was implanted with 4 
cells/scaffold constructs. After implantation for 6 and 12 weeks, the mice were sacrificed to retrieve the 
implants. The gross appearance of the harvested implants after 12 weeks of implantation was observed with 
an OLYMPUS DP22 light microscope (Olympus, Japan). The facade and lateral areas of the implants were 
measured by an OLYMPUS CellSens Standard software (Olympus, Japan). The initial facade and lateral 
areas of the hydrated cells/scaffold constructs before implantation were also measured. Each experiment was 
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carried out in triplicate. 
3.3.10 Histological and immunohistochemical evaluations of in vivo implants 
The harvested implants were washed with PBS for 3 times and fixed in 10% neutral-buffered formalin 
solution at room temperature for 48 hours. The samples were then decalcified in decalcifying solution B 
(Wako Pure Chemical Industries, Ltd., Japan) for 48 hours, dehydrated in serial dilutions of ethanol and 
embedded in paraffin. The samples were sectioned to get the vertical cross-sections of a thickness of 7 μm. 
The cross-sections were stained with hematoxylin and eosin (H&E, MUTO Pure Chemicals CO., Ltd., 
Japan). The stained cross-sections were observed under a light microscope. 
The cross-sections were also immunohistochemically stained for collagen type I (Col I) and osteocalcin 
(OCN). The deparaffinized cross-sections were incubated with proteinase K for antigen retrieval for 10 
minutes, peroxidase blocking solution for 5 minutes and 10% goat serum solution for 30 minutes. And then 
the cross-sections were incubated with the primary antibodies of rabbit monoclonal anti-human collagen I 
(working concentration, 1: 1500; Abcam, UK) and rabbit polyclonal anti-human osteocalcin (5 μg/mL 
working concentration; Abcam, UK) for 2 hours followed by incubation with the peroxidase-labeled 
polymer-conjugated secondary antibody (DakoCytomation EnVision+; Dako, Denmark) for 1 hour. The 
cross-sections were finally incubated with 3,3’-diaminobenzidine (DAB; Liquid DAB+ Substrate 
Chromogen System, Dako) for 10 minutes to develop color. Nuclei were counterstained with hematoxylin. 
All procedures were performed at room temperature.  
3.3.11 PCR assay of in vivo implants 
After 12 weeks of implantation, the harvested implants were cleaned of any surrounding soft tissue and 
washed with PBS for 3 times. All the experiment procedures to analyze the expression of 
osteogenesis-related genes were the same as those used for in vitro cell culture samples. Every 3 samples 
were used for the analysis.   
3.3.12 Statistical analysis 
All data were reported as the mean ± standard deviation (SD). One-way ANOVA statistical analysis was 
performed to evaluate the significance of the experimental data followed by a Tukey’s post hoc test for 
pairwise comparison. All statistical analyses were executed using Kyplot 2.0 beta 15. When the p-value was 
less than 0.05, the difference was considered significant. The data were indicated with * for p < 0.05, ** for 
p < 0.01 and *** for p < 0.001. 
3.4 Results  
3.4.1 Characteristics of NPs and BCP/Col composite scaffolds 
The BCP NPs were prepared by reacting a Ca(NO3)2·4H2O aqueous solution with a (NH4)2HPO4 
aqueous solution. The DEX@BCP NPs were prepared by adding DEX in the Ca(NO3)2·4H2O aqueous 
solution during formation of the BCP NPs. The DEX@BCP NPs prepared with 2.25, 4.5 and 6.75 mg of 
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DEX were referred as DEX1@BCP NPs, DEX2@BCP NPs and DEX3@BCP NPs, respectively. TEM 
observation showed the BCP NPs were short rod-like and most of them were agglomerated into needle-like 
crystals (Fig. 3.1a). Incorporation of the DEX didn’t change the size and morphology of the BCP NPs (Fig. 
3.1b-d). The elemental mapping (Fig. 3.2) showed that Ca and P were detected both in the BCP NPs and in 
the DEX3@BCP NPs, while element F derived from DEX was only detected in the DEX3@BCP NPs. 
Elemental mapping of the DEX3@BCP NPs showed that element F was uniformly distributed across the 
entire DEX3@BCP NPs, indicating existence of DEX within the DEX3@BCP NPs. As shown in our 
previous study, both BCP NPs and DEX@BCP NPs were negatively charged and incorporation of DEX 
decreased the zeta potential of the BCP NP. The BCP NPs and DEX@BCP NPs had larger hydrodynamic 
size than their size measured from TEM images, indicating their agglomeration in aqueous solution [29]. The 
BCP NPs were hybridized with collagen to prepare the BCP/Col composite scaffolds by using pre-prepared 
ice particulates as a porogen material to control the porous structures. Different mass ratio of BCP NPs and 
collagen was used to optimize the preparation condition. SEM observation showed that the pore structures of 
the BCP/Col composite scaffolds prepared with different mass ratio of BCP NPs/collagen had obvious 
difference. Although all the BCP/Col composite scaffolds had many spherical large pores, most of the large 
pores in the BCP/Col composite scaffold prepared with the mass ratio of BCP NPs/collagen of 2: 1 were not 
well interconnected (Fig. 3.3a, f). When the mass ratio of BCP NPs/collagen decreased, the spherical large 
pores became more interconnected by more small pores. The small pores were formed at the wall of the 
spherical large pores and their number increased with the decrease of the mass ratio of BCP NPs/collagen. 
SEM observation at a high magnification showed that the BCP NPs could be observed at the surfaces of the 
spherical large pores in the BCP/Col composite scaffolds. The surface roughness of the spherical large pores 
decreased with the decrease of mass ratio of BCP NPs/collagen. When the mass ratio of BCP NPs/collagen 
was 1: 1, the BCP/Col composite scaffold had similar porous structure to that of the control Col scaffold (Fig. 
3.3d, e, i, j).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1. TEM images of the prepared BCP NPs (a), DEX1@BCP NPs (b), DEX2@BCP NPs (c) and 
DEX3@BCP NPs (d). 
 
Analysis of the pore size (Fig. 3.3k) showed that there was no significant difference of the size of  
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Fig. 3.2. Dark-field TEM images (a, e) and elemental mapping images of the BCP NPs (b-d) and DEX3@BCP NPs (f-h). 
Elementary analysis of calcium (b, f), phosphorus (c, g) and fluorine (d and h) were carried out. The intensity of the signals for the 
element of Ca, P, and F are shown in yellow, green and red colors, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3. SEM images (a-j) of the cross-sections of the Col scaffold and BCP/Col composite scaffolds prepared with a different 
mass ratio of BCP NPs/collagen (BCP: Col) at low (a-e) and high (f-j) magnifications. Scale bar: (a-e), 500 µm; (f-j), 50 µm. 
Diameter of the large pores and the small pores in the Col scaffold and the BCP/Col composite scaffolds prepared with a different 
mass ratio of BCP NPs/collagen (k). Young’s modulus of the hydrated scaffolds of the Col and BCP/Col prepared with a different 
mass ratio of BCP NPs/collagen (l). Data represent mean ± SD, N = 3. Significant difference: *, p < 0.05; **, p < 0.01; ***, p < 
0.001. 
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spherical larges pores in the control Col scaffold and all the 4 types of BCP/Col composite scaffolds prepared 
at different ratio of BCP NPs/collagen. The size of the spherical large pores was in a range of 405~450 µm, 
which was predominantly determined by the pre-prepared ice particulates used as the porogen material. On 
the other hand, the size of small pores interconnecting the spherical large pores was dependent on the mass 
ratio of BCP NPs/collagen. The size of small pores increased from 20.0 ± 6.2 µm to 65.3 ± 23.5 µm when the 
mass ratio of BCP NPs/collagen decreased from 2: 1 to 1: 1. The size of small pores in the BCP/Col 
composite scaffold prepared at BCP: Col mass ratio of 1: 1 had no significant difference from that in the 
control Col scaffold (72.7 ± 19.8 µm). 
A mechanical compression test was used to measure the Young’s modulus of the scaffolds. The Young’s 
modulus of all the BCP/Col composite scaffolds was significantly higher than that of the control Col scaffold 
(Fig. 3.3l). Hybridization with BCP NPs reinforced the scaffolds. The mass ratio of BCP NPs/collagen had 
evident effect on the Young’s modulus. The Young’s modulus of the BCP/Col composite scaffolds decreased 
with the decrease of mass ratio of BCP NPs/collagen. Noticeably, even with the lowest mass ratio of BCP 
NPs/collagen, the Young’s modulus of the BCP/Col composite scaffold was 2.5-fold higher than that of the 
Col scaffold. These results indicated that the BCP had opposite effects on the pore structure and mechanical 
property of the composite scaffolds. Both interconnected pore structure and high mechanical property are 
important properties of porous scaffolds. The BCP/Col composite scaffold prepared at the BCP NPs/collagen 
mass ratio of 1: 1 had the best interconnected pore structure and still very high mechanical property when 
being compared with other BCP/Col composite scaffolds and the control Col scaffold. Therefore, the BCP 
NPs/collagen mass ratio of 1: 1 was chosen as the optimal condition for the preparation of BCP/Col scaffolds. 
This mass ratio was also used for preparation of the DEX1@BCP/Col, DEX2@BCP/Col and 
DEX3@BCP/Col composite scaffolds for the following experiments. 
3.4.2 Characteristics of DEX@BCP/Col composite scaffolds 
The BCP/Col, DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col composite scaffolds that were 
used for cell culture were prepared by the above described method with the NPs/collagen mass ratio of 1: 1. 
Their pore structures and mechanical properties were compared with those of control Col scaffold (Fig. 3.4). 
All the scaffolds had well interconnected large pores with the same size. The spherical large pores were 
distributed homogeneously throughout the scaffolds and their size was almost equal to the size of the 
pre-prepared ice particulates used as porogen material (Fig. 3.4k). The size of the small pores was also the 
same for all the scaffolds. The spherical large pores should be derived from the pre-prepared ice particulates, 
while the small pores should be derived from the new ice crystals formed during the pre-freezing process. 
The small pores provided good interconnections among the spherical large pores. The average size of small 
pores was around 70 µm (Fig. 3.4k), making the scaffolds well interconnected and the porosity of all the 
scaffolds was higher than 97.8 % (Table 3.1). The high porosity and good interconnectivity should be 
beneficial for cell migration and spatial distribution. The surface of spherical large pores in the composite 
scaffolds was much rougher than that of the control Col scaffold (Fig. 3.4f). The BCP NPs and DEX@BCP 
NPs were homogeneously embedded into the collagen matrices on the pore walls and therefore increased the 
pore surface roughness of the composite scaffolds (Fig. 3.4g-j). 
The Young’s modulus of BCP/Col, DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col scaffolds 
was measured and compared with that of the Col scaffold (Fig. 3.4l). The BCP/Col, DEX1@BCP/Col, 
DEX2@BCP/Col and DEX3@BCP/Col composite scaffolds showed similar Young’s modulus, which was 
significantly higher than that of the control Col scaffold. Incorporation of DEX in the BCP NPs did not affect 
the porous structures and mechanical properties of the composite scaffolds. 
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Fig. 3.4. SEM images (a-j) of cross-sections of the Col scaffold and BCP/Col composite scaffolds prepared with a different mass 
ratio of BCP NPs/collagen (BCP: Col) at low (a-e) and high (f-j) magnifications. Scale bar: (a-e), 500 µm; (f-j), 50 µm. Diameter of 
the large pores and the small pores in the Col scaffold and the BCP/Col composite scaffolds prepared with a different mass ratio of 
BCP NPs/collagen (k). Young’s modulus of the hydrated scaffolds of the Col and BCP/Col prepared with a different mass ratio of 
BCP NPs/collagen (l). Data represent mean ± SD, N = 3. Significant difference: *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
 
Table 3.1. Porosity of Col, BCP/Col, DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col scaffolds. 
 
 
 
 
 
3.4.3 DEX release from DEX@BCP/Col composite scaffolds 
The loading amount of DEX in the DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col was 
387.9 ± 46.8, 705.5 ± 62.3 and 856.2 ± 70.4 ng/scaffold, respectively. The loading amount and cumulative 
release amount of DEX from the DEX@BCP/Col scaffolds increased with increasing of the DEX feeding 
amount in the DEX@BCP NPs (Fig. 3.5a). The release of DEX was observed over a 35-day period. After 
incubation for 35 days, the cumulative release amount of DEX from the DEX1@BCP/Col, DEX2@BCP/Col 
and DEX3@BCP/Col was 339.9 ± 35.8, 553.5 ± 38.3 and 712.5 ± 57.1 ng/scaffold, respectively.  Based on 
the DEX loading amount, the percentage of released DEX was calculated (Fig. 3.5b). After 35 days, the DEX 
Sample Col BCP/Col DEX1@BCP/Col DEX2@BCP/Col DEX3@BCP/Col 
Porosity (%) 98.6 ± 0.3 98.1 ± 0.6 97.8 ± 0.5 98.0 ± 0.7 98.3 ± 0.2 
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release percentage from the DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col was 87.6 ± 9.2 %, 
78.4 ± 5.2 % and 83.2 ± 6.7 %, respectively. 
3.4.4 Cell adhesion, distribution, viability and proliferation during in vitro culture 
The biocompatibility of Col, BCP/Col and DEX@BCP/Col composite scaffolds was evaluated by 
examination of adhesion, distribution, viability and proliferation of hMSCs in the scaffolds. For all the Col, 
BCP/Col and DEX@BCP/Col composite scaffolds, hMSCs could be seeded homogeneously throughout the 
whole scaffolds (Fig. 3.6). SEM observation showed that hMSCs well adhered on the walls of the spherical 
large pores in all the scaffolds (Fig. 3.7a). When compared to the control Col scaffold, hMSCs seeded in the 
BCP/Col and DEX@BCP/Col scaffolds showed more filopodia and more widely spread. Live/dead staining 
was performed to evaluate cell viability after 7 days culture. Most of the hMSCs were alive (green 
fluorescence) and few dead cells (red fluorescence) were observed in all the scaffolds. The results indicated 
high viability of hMSCs when being cultured in the scaffolds (Fig. 3.7b). DNA quantification showed that 
hMSCs proliferated in the porous scaffolds in a time-dependent manner (Fig. 3.7c). After being cultured for 
4 weeks, the cell number in the BCP/Col was significantly higher than that of other groups. The cell number 
in the DEX1@BCP/Col and DEX2@BCP/Col was significantly higher than that of Col+DEX. These results 
indicated BCP NPs showed obvious stimulation to the proliferation of hMSCs, while DEX showed a little 
inhibition to the proliferation of hMSCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5. Cumulative amount (a) and percentage (b) of the released DEX from the DEX1@BCP/Col, DEX2@BCP/Col and 
DEX3@BCP/Col composite scaffolds. Data represent means ± SD, N=3. 
3.4.5 ALP staining and ALP activity assay 
ALP staining (Fig. 3.8a) demonstrated that a slightly more intense staining was observed in the cells 
cultured in the BCP/Col scaffold when compared to the Col group, while the staining intensity in all the 
DEX-contained groups was obviously stronger than that of the groups without DEX. The staining intensity 
of the BCP/Col+DEX was stronger than those of the Col+DEX and DEX1@BCP/Col, while similar to those 
of the DEX2@BCP/Col and DEX3@BCP/Col. The results of ALP activity assay corresponded well with that 
of the ALP staining (Fig. 3.8b). The ALP activity in all the culture conditions increased in an order of Col < 
BCP/Col< DEX1@BCP/Col < Col+DEX ≈ DEX2@BCP/Col < BCP/Col+DEX < DEX3@BCP/Col. The 
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results of ALP staining and ALP activity assay demonstrated that the BCP NPs showed some stimulation on 
osteogenic differentiation of hMSCs. The DEX@BCP/Col composite scaffolds with a higher loading amount 
of DEX resulted in more significant stimulation on the osteogenic differentiation of hMSCs. 
3.4.6 Expression of osteogenesis-related genes of in vitro samples 
The expression of osteogenic marker genes in hMSCs was analyzed by RT-PCR after 28 days culture in 
the scaffolds (Fig. 3.9). The expression of ALP, RUNX2, IBSP and BMP-2 genes was up-regulated by the 
BCP/Col and DEX@BCP/Col scaffolds when compared to the Col scaffold. ALP and RUNX2 genes showed 
similar expression patterns, being up-regulated in an increasing order of Col< BCP/Col < Col+DEX < 
DEX1@BCP/Col < BCP/Col+DEX < DEX2@BCP/Col< DEX3@BCP/Col (Fig. 3.9a, 3.9c). IBSP gene 
expression was up-regulated in an order of Col< Col+DEX < BCP/Col < BCP/Col+DEX < DEX1@BCP/Col 
< DEX2@BCP/Col< DEX3@BCP/Col (Fig. 3.9b). BMP-2 gene expression increased in an order of Col< 
BCP/Col < Col+DEX < DEX1@BCP/Col < DEX2@BCP/Col < BCP/Col+DEX < DEX3@BCP/Col (Fig. 
3.9d). The results suggested that both BCP NPs and DEX showed some stimulation to the expression of 
osteogenic genes. The DEX@BCP/Col scaffolds stimulated osteogenic gene expression of hMSCs in a DEX 
amount-dependent manner. The composite scaffolds containing higher amount of DEX (DEX2@BCP/Col 
and DEX3@BCP/Col) had better stimulatory effects on osteogenic gene expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6. Cell distributions in the Col scaffold (a) and DEX1@BCP/Col composite scaffold (b) after 1 day of 
culture. Cell nuclei were stained by DAPI and observed under a fluorescence microscope. The blue 
fluorescence indicates cell nuclei labelled by DAPI. 
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3.4.7 Gross appearance and histological analysis of in vivo implants 
The cells/scaffold constructs were implanted into the dorsa of nude mice for 6 and 12 weeks. Gross 
appearance of the implants after 12 weeks implantation is shown in Fig. 3.10a. The Col and Col+DEX 
implants were flesh-colored with evident deformation of their shapes. The implants of the composite 
scaffolds were reddish, which should be due to regeneration of capillary blood vessels in the scaffolds. 
Measurement of the facade and lateral areas showed that the size of the Col and Col+DEX implants 
significantly decreased when compared to their initial size. However, the size of the composite scaffold 
implants had no obvious change (Fig. 3.10b, c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7. SEM images of the cross-sections of the Col, BCP/Col and DEX@BCP/Col scaffolds after 1-day in 
vitro culture (a). Live/dead staining of the hMSCs in the scaffolds after 7 days in vitro culture (b). 
Quantification of DNA content in the scaffolds after 1, 7, 14 and 28 days in vitro culture (c). Data represent 
mean ± SD, N = 4. Significant difference: *, p < 0.05; **, p < 0.01; ***, p < 0.001.  
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H&E staining showed clear cell infiltration, uniform cell distribution and homogenous deposition of 
ECM throughout all the implants (Fig. 3.10d, e). After 6 weeks, new bone formation was observed in the 
BCP/Col, BCP/Col+DEX, DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col implants while not 
evident in the Col implant. The signs for new bone formation in the DEX1@BCP/Col, DEX2@BCP/Col and 
DEX3@BCP/Col implants were more evident than those in the BCP/Col and BCP/Col+DEX implants. 
Furthermore, new blood vessels that were characterized by the presence of lining endothelial cells and red 
blood cells were observed in the BCP/Col, BCP/Col+DEX, DEX1@BCP/Col, DEX2@BCP/Col and 
DEX3@BCP/Col implants (Fig. 3.11). After 12 weeks implantation, the new bone formation became more 
obvious than the 6 weeks implants, in particular for the BCP/Col+DEX, DEX1@BCP/Col, DEX2@BCP/Col 
and DEX3@BCP/Col implants. The area of the newly formed bone in the DEX3@BCP/Col was much 
higher than those in the DEX1@BCP/Col and DEX2@BCP/Col implants. Plenty of new blood vessels were 
formed in the BCP/Col, BCP/Col+DEX and DEX@BCP/Col implants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.8. ALP staining (a) and ALP activity assay (b) of the hMSCs in the Col, BCP/Col and DEX@BCP/Col 
scaffolds after 14 days in vitro culture. Data represent mean ± SD, N = 3. Significant difference: *, p < 0.05; 
**, p < 0.01; ***, p < 0.001. ALP staining (a) and ALP activity assay (b) of the hMSCs in the Col, BCP/Col 
and DEX@BCP/Col scaffolds after 14 days in vitro culture. Data represent mean ± SD, N = 3. Significant 
difference: *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
3.4.8 Immunohistochemical staining of osteogenesis-related proteins 
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To detect the presence of osteogenesis-related proteins, immunohistochemical staining of human Col I 
and OCN was carried out for the 6 and 12 weeks implants (Fig. 3.12). The Col I and OCN proteins were 
detected in all the implants except the Col implant. Expression of Col I and OCN in the BCP/Col+DEX, 
DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col implants was much higher than that in the 
Col+DEX and BCP/Col implants after both 6 and 12 weeks implantation. The expression of Col I and OCN 
in the DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col implants was the highest. The results 
indicated the osteogenesis degree in the DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col was 
much higher than that of the other groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.9. Gene expression of ALP (a), IBSP (b), RUNX2 (c) and BMP-2 (d) of the hMSCs in the Col, BCP/Col 
and DEX@BCP/Col scaffolds after 28 days in vitro culture. Data represent mean ± SD, N = 3. Significant 
difference: *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
3.4.9 Expression of osteogenesis-related genes of in vivo implants 
The expression of osteogenic marker genes after in vivo implantation for 12 weeks was analyzed by 
RT-PCR (Fig. 3.13). The results showed that the expression of ALP, RUNX2, IBSP and BMP-2 genes was 
up-regulated by the BCP/Col, DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col implants compared 
to the Col implant. When compared to the Col+DEX implant, ALP gene was slightly up-regulated in the 
BCP/Col, BCP/Col+DEX, DEX1@BCP/Col and DEX2@BCP/Col implants, while significantly 
up-regulated in the DEX3@BCP/Col implant (Fig. 3.13a); IBSP was significantly up-regulated in the 
BCP/Col+DEX, DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col implants (Fig. 3.13b); RUNX2 
and BMP-2 were slightly up-regulated in the BCP/Col and BCP/Col+DEX implants, while significantly 
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up-regulated in the DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col implants (Fig. 3.13c, d). The 
PCR results indicated the DEX1@BCP/Col, DEX2@BCP/Col and DEX3@BCP/Col implants showed the 
highest expression level of osteogenesis-related genes, which increased with the increase of DEX loading 
amount. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.10. Gross appearance (a), facade area (b) and lateral area (c) of the cells/scaffold constructs of the Col, 
BCP/Col and DEX@BCP/Col scaffolds after 12 weeks implantation. Scale bar: 2.0 mm. Data represent 
mean ± SD, N = 3. Significant difference: *, p < 0.05; **, p < 0.01; ***, p < 0.001. Photomicrographs of the 
H&E staining of the decalcified sections of the implants after in vivo implantation for 6 weeks (d) and 12 
weeks (e). Yellow arrows indicate the new blood vessels. Green stars indicate the new bone formation. 
3.5 Discussion 
Mimicking the osteogenic matrices of bone is an important strategy to prepare biomimetic scaffolds for 
bone TE. Composition of natural bone is about 35% organic (primarily collagen type I) and about 65% 
inorganic (nanocrystalline calcium phosphate, CaP) [32]. Both collagen and CaP have been used to prepare 
the bone TE scaffolds. Although collagen scaffolds have shown good biological performance, they have the 
problem of insufficient mechanical stability [33]. On the other hand, CaP scaffolds have good mechanical 
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property while lacking appropriate degradability and pore structure [34]. Combination of collagen and CaP 
may be a useful strategy for preparation of porous scaffolds with a better performance for bone TE. In this 
study, biphasic calcium phosphate nanoparticles (BCP NPs) were hybridized with collagen to prepare 
BCP/Col composite scaffolds. Ice particulates, which are nontoxic and easily removed through freeze-drying, 
were used as the porogen material to control the pore structures such as pore size and interconnectivity [35]. 
In natural bone, the mass ratio of inorganic to organic compositions is about 2: 1. The BCP/Col composite 
scaffold prepared with the BCP NPs/collagen mass ratio of 2: 1 exhibited the highest mechanical property. 
However, most of the spherical large pores formed in the 2: 1 BCP/Col composite scaffold were isolated 
pores without interconnection (Fig. 3.3). Pore interconnectivity is extremely important for bone TE scaffolds 
to facilitate cell seeding, migration and distribution throughout the scaffolds [36]. When ice particulates were 
used as the porogen material, the spherical large pores formed in scaffold should be the negative replicas of 
the ice particulates, while the interconnective small pores should be the replicas of the ice crystals formed in 
situ to connect the large ice particulates during the pre-freezing process [37]. The BCP NPs in the BCP 
NPs/Col/ice particulates mixture might influence the formation of new ice crystals. In particular, too many 
BCP NPs at the BCP NPs/collagen mass ratio of 2: 1 might inhibit the formation of the ice crystals 
connecting the porogen ice particulates. When the mass ratio of BCP NPs/collagen was decreased to 1: 1, the 
BCP/Col composite scaffold had the same pore structure as that of the control Col scaffold and its 
mechanical property was still very high (Fig. 3.3). Therefore, the BCP NPs/collagen mass ratio of 1: 1 was 
chosen as the optimal ratio to prepare the BCP/Col and DEX@BCP/Col composite scaffolds for other 
experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.11. Presence of the newly formed blood vessels in the cells/scaffold constructs after implantation for 6 
and 12 weeks. The yellow arrows indicate the red blood cells in the blood vessels. The blue arrows indicate 
the endothelial cells lining the blood vessels. 
 
Bone tissue has a hierarchical structure ranging from macroscale to nanoscale [38]. Many studies have 
attempted to mimic architecture of natural bone [39, 40]. In this study, the nano-sized DEX@BCP NPs were 
distributed homogenously on the walls of the DEX@BCP/Col composite scaffolds, providing nanocomposite 
surfaces for cell adhesion (Fig. 3.4). Due to the well-controlled pore structures with nanoscale features, 
hMSCs could migrate and adhere in the DEX@BCP/Col composite scaffolds and showed homogenous 
distribution throughout the scaffolds (Fig. 3.6, Fig. 3.7a). The cells had high viability and proliferated in the 
scaffolds (Fig. 3.7b, c). BCP NPs showed some stimulatory effects on proliferation of hMSCs, which was in 
accordance with previous studies [7, 41]. These results indicated good biocompatibility of the 
DEX@BCP/Col composite scaffolds. 
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Fig. 3.12. Immunohistochemical staining of Col I (a) and OCN (b) in the decalcified sections of the 
cells/scaffold constructs of the Col, BCP/Col and DEX@BCP/Col scaffolds after 6 weeks and 12 weeks 
implantation. The sections were counterstained with hematoxylin. The brown signals show the presence of 
Col I and OCN in the cells/scaffold constructs. The blue signals show the cell nuclei. 
 
Osteoinductive cues are important for bone TE [42]. As a useful osteoinductive factor, DEX was 
incorporated into the BCP NPs and further hybridized with collagen to prepare the DEX@BCP/Col 
composite scaffolds. DEX was loaded in the BCP NPs during the nucleation and growth of the crystals of the 
BCP NPs. The low molecular weight molecule DEX should be physically locked in BCP NPs. When the 
DEX-loaded BCP NPs were degraded, DEX was released [29]. The DEX@BCP/Col scaffolds showed a 
controlled and sustained release profile of DEX which could last for 35 days (Fig. 3.5). The released amount 
of DEX could be regulated by varying the initial DEX loading amount in the DEX@BCP NPs. From the 7th 
to 31th day of cell culture, the average release amount of DEX from the DEX1@BCP/Col, DEX2@BCP/Col 
and DEX3@BCP/Col scaffolds during every three days was 36.9 ± 17.4, 62.7 ± 29.5 and 74.7 ± 36.0 
ng/scaffold, respectively (Fig. 3.5a). 3 days was the medium change time of the positive control that was 
cultured in medium containing 100 nM (39.6 ng/mL) free DEX. The released amount of DEX from the 
DEX@BCP/Col scaffolds during cell culture could match the amount of free DEX supplemented in the 
positive control samples. 
Rapid bone regeneration requires effective osteogenic differentiation of stem cells within the scaffolds 
[43]. ALP activity and gene expression of ALP, RUNX2, IBSP and BMP-2 demonstrated that hMSCs 
cultured in the DEX@BCP/Col composite scaffolds showed obvious osteogenic differentiation. The 
DEX@BCP/Col composite scaffolds with different initial loading amount of DEX stimulated the osteogenic 
differentiation in a DEX amount-dependent manner (Fig. 3.8 and 3.9). The in vivo implantation further 
confirmed the enhanced osteogenic differentiation of hMSCs in the DEX@BCP/Col scaffolds. From the 
histological results, ectopic new bone formation in the DEX@BCP/Col composite scaffolds was observed 
(green stars in Fig. 3.10d, 3.10e). IHC staining for Col I and OCN, as well as gene expression of ALP, 
RUNX2, IBSP and BMP-2 further proved the osteogenic differentiation of hMSCs and new bone 
regeneration in the DEX@BCP/Col composite scaffolds in the in vivo environment (Fig. 3.12 and 3.13). All 
the in vitro and in vivo analyses confirmed the DEX@BCP/Col scaffolds stimulated osteogenic 
differentiation of hMSCs. 
Another interesting result in this study is the regeneration of capillary blood vessels in the BCP/Col and 
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DEX@BCP/Col composite scaffolds after in vivo implantation (Fig. 3.10d, e, Fig. 3.11). Bone healing is 
highly dependent on adequate angiogenesis [44]. Some previous studies have reported that CaP can stimulate 
the angiogenesis of scaffolds due to the enhanced adsorption of angiogenesis-related growth factors and 
constant release of Ca2+ which facilitate angiogenesis [45]. The embedded BCP NPs in the DEX@BCP/Col 
composite scaffolds showed similar stimulatory effect on angiogenesis. This should be another advantage of 
the DEX@BCP/Col composite scaffolds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.13. Gene expression of ALP (a), IBSP (b), RUNX2 (c) and BMP-2 (d) of the hMSCs in the Col, 
BCP/Col and DEX@BCP/Col scaffolds after 12 weeks implantation. Data represent mean ± SD, N = 3. 
Significant difference: *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
 
Based on the results, a mechanism of promotive effect of the DEX@BCP/Col composite scaffolds on 
osteogenic differentiation of hMSCs was proposed. Firstly, the well-controlled microporous structures of the 
DEX@BCP/Col composite scaffolds allowed cell migration and homogeneous cell distribution. The 
nano-structured pore surfaces promoted cell adhesion. Secondly, the good mechanical property of the 
DEX@BCP/Col composite scaffolds supported cell proliferation and ECM production. Thirdly, degradation 
of the DEX@BCP/Col composite scaffolds could sustainably release DEX, Ca2+ and PO43- ions in an 
appropriate amount. The released DEX, Ca2+ and PO43- ions could function synergistically to up-regulate the 
expression of osteogenic genes and proteins, resulting in the osteogenic differentiation of hMSCs. 
Angiogenesis was also promoted by the constant release of Ca2+ ions to facilitate the metabolic activities. All 
these factors worked together to promote osteogenic differentiation of hMSCs for new bone regeneration. 
In summary, combination of porous Col scaffold and DEX@BCP NPs exerted synergistic effects on the 
osteogenesis and angiogenesis. Considering the advantages of porous collagen scaffold and the superior 
performance of the DEX@BCP NPs on the osteogenic differentiation of hMSCs, combination of these 
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factors may provide an effective strategy for bone TE. On the other hand, although the Young’s modulus of 
the DEX@BCP/Col composite scaffolds was 2.5-fold higher than the porous collagen scaffold and much 
higher than some other literature-reported NPs/polymer composite scaffolds [46-48], it was still much lower 
than that of natural bone. For practical applications, the DEX@BCP/Col composite scaffolds can be used as 
substitution for non-weight-bearing bones such as the skull cranial bones, or as substitution for 
weight-bearing bones which can be physically fixed at initial stage of the bone reconstruction to avoid 
load-bearing. Rapid generation of new bone tissue in the composite scaffolds can be expected due to their 
excellent osteoconductivity and osteoinductivity, during which the mechanical property of the implants can 
dramatically increase until the whole scaffolds are replaced by newly formed bone tissue. 
3.6 Conclusions 
DEX-loaded BCP NPs/Col composite scaffolds with precisely controlled pore structures and a sustained 
release of DEX were prepared. The DEX@BCP NPs were distributed homogeneously on the walls of the 
scaffolds, enhancing the mechanical property and roughness of the scaffolds. The sustained and prolonged 
release of DEX from the scaffolds could last for 35 days. The DEX@BCP/Col scaffolds with different DEX 
loading amount had good biocompatibility and stimulated osteogenic differentiation of hMSCs and new bone 
tissue regeneration during in vitro culture and in vivo implantation. The DEX@BCP/Col composite scaffold 
with the highest DEX loading amount showed the most promising potential for bone tissue engineering. The 
DEX@BCP/Col composite scaffolds should provide some useful guidance for bone tissue engineering.  
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Promoted angiogenesis and osteogenesis by dexamethasone-loaded 
calcium phosphate nanoparticles/collagen composite scaffolds with 
microgroove network 
 
 
 
 
4.1 Summary 
Reconstruction of large bone defects remains a significant clinical challenge as current approaches 
involving surgery or bone grafting often do not yield satisfactory outcomes. For the artificial bone substitutes 
used for bone grafting, angiogenesis plays a pivotal role directly leading to the final success of newly 
regenerated bone. In this part, dexamethasone-loaded biphasic calcium phosphate nanoparticles/collagen 
(DEX@BCP/Col) composite scaffolds with several types of concave microgrooves were prepared for 
simultaneous promotion of angiogenesis and osteogenesis. The microgrooves in the composite scaffolds 
were supposed to guide assembly of HUVECs into well aligned tubular structures, thus promoting rapid 
angiogenesis. The scaffolds were used for co-culture of HUVECs and hMSCs. Subcutaneous implantation in 
mice showed that more blood vessels and newly formed bone were observed in the microgrooved composite 
scaffolds than the control scaffold without microgrooves. The composite scaffolds bearing parallel 
microgrooves with a concave width of 290 µm and a convex ridge width of 352 µm had the highest 
promotion effect on angiogenesis and osteogenesis among the parallelly microgrooved composite scaffolds. 
The microgroove network had further superior effect than the parallel microgrooves. The results suggested 
that microgrooves in the composite scaffolds facilitated angiogenesis and stimulated new bone formation. 
The microgrooved composite scaffolds should be useful for repair of large bone defects.   
4.2 Introduction 
Although bone is one of the regenerative tissues, further intervention is needed when the bone defect 
beyond a certain critical size [1]. Nowadays, the use of autografts and allografts remains to be the gold 
standard in reparation of large bone defects. However, they have some drawbacks including limited sources, 
risk of infection and complications, immunological rejection and donor site morbidity [2]. Consequently, 
more and more attention has been drawn to design artificial bone substitutes with desirable biological 
properties for large bone defects. Healing of bone defects is a complicated process resulting from the 
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reciprocal actions of multiple cellular, molecular, biochemical and biomechanical cues, among which 
angiogenesis of the bone substitutes plays a pivotal role directly leading to the final success of newly 
regenerated bone [3]. Presence of functional vascular network within the implants is essential for the timely 
furnishing of oxygen, nutrients and signal molecules, as well as taking metabolic waste and carbon dioxide 
away [4]. Blood vessel invasion happens once the engineered tissue or material is implanted, but the vascular 
growth is too slow and almost negligible in providing sufficient blood supply, giving rise to osteonecrosis 
and trauma non-union, which is believed to be caused by cell death in the regions far from the capillaries [5]. 
Considering diffusion limit of oxygen and nutrients, generally any reconstructed tissue thicker than 400 μm 
must be vascularized to survive [6]. Therefore, a desirable scaffold for bone tissue engineering should have 
the functions to facilitate both angiogenesis and osteogenesis during bone regeneration process.   
Incorporation of biological and pharmaceutical factors such as vascular endothelial growth factor 
(VEGF) and fibroblast growth factor in tissue engineering scaffolds has been generally used for promotion of 
angiogenesis [7, 8], which has achieved only limited success. Concerns about the usage of these growth 
factors or cytokines still remain, such as instability, uncontrollable dose, high cost, short half-life and 
increased risk for tumor. Thus, development of an alternative strategy to effectively induce angiogenesis of 
the bone substitutes hence to achieve a better bone regeneration in the large bone defects is strongly 
desirable.  
Except for angiogenetic function, bone tissue engineering scaffolds should also have osteoinductive and 
osteoconductive functions to enhance regeneration of large size bone defects. Protein growth factors such as 
transform growth factor- β and bone morphogenetic protein-2 (BMP-2) have been frequently incorporated in 
scaffolds to increase their osteogenesis-promoting effects [9, 10]. Nevertheless, use of protein growth factors 
to promote bone regeneration has the same problems as mentioned above. Dexamethasone (DEX), which is 
an osteogenic inducer with low molecular weight, high potency and long-acting properties, has been used to 
substitute protein growth factors for promotion of osteogenesis. DEX has been incorporated into biphasic 
calcium phosphate nanoparticles (BCP NPs) to combine the synergistically osteogenic effects of DEX as 
well as the calcium and phosphorous ions released from the BCP NPs [11].  
Therefore, in the present study, composite scaffolds with microgroove network were prepared for 
simultaneous promotion of angiogenesis and osteogenesis. DEX-loaded BCP NPs were hybridized with 
collagen to prepare DEX-BCP-Col composite scaffolds. During preparation of the composite scaffolds, 
pre-fabricated ice particulates were used as a pore-forming agent to control the pore size and increase pore 
interconnectivity. Furthermore, concave microgrooves were introduced in the composite scaffolds by using 
micropatterned ice lines or ice network. The combination of DEX, BCP NPs and collagen should have 
synergistic effects on osteogenic differentiation of stem cells. The microgrooves in the composite scaffolds 
were supposed to guide assembly of human umbilical vascular endothelial cells (HUVECs) into well aligned 
tubular structures thus promoting rapid angiogenesis. The composite scaffolds were used for co-culture of 
HUVECs and human bone marrow-derived mesenchymal stem cells (hMSCs). Effects of the scaffolds on 
angiogenesis and osteogenesis were investigated by in vitro cell culture and in vivo implantation.  
4.3 Materials and methods 
4.3.1 Preparation of DEX@BCP NPs  
Gelatin DEX-loaded biphasic calcium phosphate nanoparticles (DEX-BCP NPs) were synthesized by 
incorporation of DEX during the formation of BCP NPs [11]. 4.5 mg of DEX (C22H29FO5, Sigma-Aldrich) 
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was dissolved in 2 mL of ethanol and then added into the 48 mL of 0.52 M calcium nitrate tetrahydrate 
(Ca(NO3)2·4H2O, Sigma-Aldrich) aqueous solution. The mixture solution was added dropwise to 33.4 mL of 
0.5 M diammonium phosphate ((NH4)2HPO4, Sigma-Aldrich) solution by a syringe pump (KD Scientific 
Inc.). The reaction was conducted under magnetic stirring (700 rpm) in a 55 °C water bath. Throughout the 
reaction, ammonium hydroxide solution (NH4OH, Sigma-Aldrich) was added dropwise into the reaction 
solution to maintain the pH at 9.5. After the reaction was maintained for 30 minutes, the slurry was aged for 
36 hours at room temperature (RT) to form the DEX-BCP NPs. The prepared DEX-BCP NPs were washed 
by dispersing them in 20 mL ethanol and shaking at 200 rpm and RT for 20 minutes followed with 
centrifugation at 8000 rpm. The washing with ethanol was repeated for 3 times to remove DEX adsorbed on 
surface of DEX-BCP NPs.  
4.3.2 Preparation of microgrooved DEX-BCP-Col composite scaffolds 
The microgrooved DEX-BCP-Col composite scaffolds were prepared by generation of parallel 
microgrooves or microgroove network in DEX-BCP-Col composite scaffolds which were prepared by 
applying pre-fabricated ice particulates as a pore-forming agent. Pure water was spayed into liquid nitrogen 
to prepare the ice particulates. The ice particulates sizing between 425 and 500 μm were obtained by using 
two sieves sizing of 425 and 500 μm [12]. Porcine type I collagen (Nitta Gelatin Inc.) was dissolving in 10% 
(v/v) ethanol aqueous solution to prepare 2.5% and 1.0% (w/v) collagen aqueous solutions. The DEX-BCP 
NPs were dispersed in 10% (v/v) ethanol aqueous solution to prepare their dispersion solution at a 
concentration of 93 mg/mL. The ice particulates, 2.5% collagen solution and DEX-BCP NPs dispersion 
solution were retained in a cooling chamber (Espec Corp.) at -5 °C for 4 hours to balance their temperature 
to -5 °C. After temperature balance, 3 mL of the pre-cooled DEX-BCP NPs dispersion solution was added 
dropwise to 11 mL of the pre-cooled 2.5% collagen solution at -5 °C and mixed well. The mass ratio of NPs 
and collagen was 1: 1 (w/w). Then, ice particulates were blended into the collagen/NPs mixture solution at a 
ratio of 1: 1 (w/v) at -5 °C. The components were mixed carefully to allow the ice particulates being 
homogeneously distributed in the mixture solution without air bubble and then poured into silicone mold 1 
(9.5 cm in length, 6.5 cm in width and 3 mm in thickness) which were placed on a copper plate wrapped by 
perfluoroalkoxy film (PFA film, Universal Co., Ltd.). The surface of the collagen/NPs/ice particulates 
mixture was platted with a spatula and a second silicone mold (9.5 cm in length, 6.5 cm in width, and 0.5 
mm in thickness) was settled exactly on mold 1 and the pre-cooled 1.0 % collagen solution were filled into 
the second mold. 
Micropatterned ice templates bearing parallel ice lines or ice cross network were prepared by a jet 
dispenser (MJET-3-CTR, Musashi Engineering Inc.). Dispensing nozzle of the dispenser was manipulated by 
a SHOT mini 200α (Musashi Engineering Inc.). PFA film-wrapped copper plate was cooled by liquid 
nitrogen. The jet dispenser moved back and forth upon the pre-cooled copper plate and ejected water droplets 
onto the plate. Water droplets instantly freeze to form parallel ice lines or ice cross network. The size of 
water droplets and hence the width of each line of the micropatterns were controlled by pumping pressure in 
the syringe and the type of nozzle. The intervals between lines were controlled by CAD programs. 4 types of 
parallel ice line templates and 1 type of ice line network template were prepared. The micropatterned ice 
templates were balanced at -5 ºC for 20 minutes and then covered on the above-mentioned second silicon 
mold. The whole construct was then frozen at -80 °C for 8 hours and lyophilized in a freeze dryer (Wizard 
2.0, SP scientific). The constructs were then cross-linked with 20 mM N-hydroxysuccimide (NHS, Wako 
Pure Chemical Industries, Ltd.) and 50 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, Peptide 
Institute Inc.) in an 80% (v/v) ethanol aqueous solution at RT under gentle shaking (~ 20 rpm) for 8 hours. 
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After cross-linking, the constructs were washed 3 times with Milli-Q water. Glycine aqueous solution (0.1 
M) was used to block the unreacted NHS residues. Then, the constructs were rinsed 6 times with water and 
lyophilized for usage of following experiments. 5 types of microgrooved DEX-BCP-Col composite scaffolds 
were prepared by using the 5 types of ice templates. They were 4 types of composite scaffolds with varied 
parallel microgrooves, and 1 type of composite scaffolds with microgroove network. The DEX-BCP-Col 
composite scaffold without microgrooves was prepared by the same procedure excepting usage of 
micropatterned template and used as a control. 
4.3.3 Characterization of NPs and scaffolds 
The morphology features of DEX-BCP NPs was visualized by a transmission electron microscope 
(TEM, JEOL 2100F). Aqueous solution containing 10 μL of DEX-BCP NPs was dropped on a carbon-coated 
copper grid to prepare the samples for TEM. The top layers and cross-sections of the microgrooved 
DEX-BCP-Col composite scaffolds and control composite scaffold were observed by a scanning electron 
microscope (SEM, JSM-5610, JEOL) at an acceleration voltage of 10 kV. All SEM images were inputted to 
an ImageJ software (ImageJ2, NIH) to quantify the concave width and convex ridge width of the 
microgrooves in the composite scaffolds. For each kind of samples, 4 images were used and every 5 
microgrooves from each image were analyzed to calculate the means and standard deviations.  
4.3.4 In vitro cell culture  
The composite scaffolds were punched into cylindrical discs (Φ12 mm × H1.5 mm) for cell culture. The 
samples were sterilized with ethylene oxide gas for 5 hours. The sterilized samples were put in 12-well cell 
culture plate and conditioned in Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich) at 37 °C for 4 
hours. The hMSCs (passage 2, Lonza) were sub-cultured using MSCBM medium (Lonza). The HUVECs 
(C2519A, Lonza) were sub-cultured using endothelial cell growth medium (EGM2, CC-3162, Lonza) that 
contained 2% FBS and vascular endothelial growth factor (VEGF). The cells were harvested using 
conventional trypsin/EDTA after reaching confluence and re-suspended in DMEM to prepare cell suspension 
solution of 2 × 106 cells/mL for cell seeding. 170 μL of the hMSCs suspension solution was dropped on the 
basal side (the side without microgrooves) of the scaffold discs. After being cultured for 3 hours, the scaffold 
discs were turned upside down and encircled by glass rings (inner diameter: 12 mm). 2 mL of the mixture 
medium (1: 1 MSCBM/EGM2) was added in each well and 200 μL of the HUVECs suspension solution was 
dropped on the top side (the side with microgrooves) of the scaffold discs. After culture for 6 hours in a 
humidified incubator at 37 °C and 5% CO2, the glass rings were removed and the medium was changed to 
the mixture medium supplemented with 10 mM β-glycerophosphate.  
4.3.5 Analysis of cell adhesion in the composite scaffolds 
SEM was used to investigate cell adhesion and distribution in the composite scaffolds. After 1 day 
culture, the cell-seeded composite scaffold discs were rinsed 3 times with PBS. The samples were then fixed 
with glutaraldehyde (2.5%) at RT for 1 hour. After being rinsed for 3 times with PBS and water respectively, 
the fixed samples were freeze-dried and their top layers and cross-sections were observed by SEM.  
4.3.6 Measurement of HUVECs assembly  
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The cells/scaffold constructs after 3 days culture were rinsed 3 times with PBS. The samples were then 
fixed by immersing in paraformaldehyde (4%) at RT for 15 minutes. The samples were washed with PBS, 
treated with Triton X-100 (0.2%) for at RT 1 hour and blocked in bovine serum albumin (BSA, 1%) at RT for 
30 minutes on a rocker. Monoclonal mouse anti-human CD31 antibody (Clone JC70A, Dako) as the primary 
antibody was diluted in BSA (1%) at 1:40 dilution. The samples were immersed into the primary 
antibody-contained solution and incubated overnight at 4 °C. After being washed with PBS, the samples 
were then incubated with goat anti-mouse IgG secondary antibody conjugated with Alexa Fluor 594 
secondary antibody (Life Technologies) at 1:500 dilution at RT for 1 hour. The cell nuclei were 
counterstained by DAPI solution at RT for 10 minutes. The stained samples were washed with PBS and 
observed by a fluorescence microscope (Olympus) or a confocal microscope (Zeiss LSM 510 Meta). 
4.3.7 In vivo implantation of composite scaffolds 
Animal experiment was approved by the Animal Experiments Committee of National Institute for 
Materials Science. The surgeries were carried out according to the committee guidelines. For in vivo 
implantation, the cells/scaffold constructs were prepared under the same condition as those used for in vitro 
cell culture. After 3 days of in vitro culture, every two same cells/scaffold constructs were stacked into one 
implant and subcutaneously implanted in the back of the 6-week-old athymic nude mice (Fig. 4.1). Every 
mouse was implanted with two implants. The mice were sacrificed to retrieve the implants after 8 weeks of 
implantation. Gross appearance of the harvested implants was observed with a light microscope (DP22, 
Olympus Corp.).  
 
 
 
 
 
 
 
 
 
Fig. 4.1. A schematic of in vitro cell culture and in vivo implantation of the microgrooved DEX-BCP/Col 
composite scaffolds. 
4.3.8 Histological and immunohistochemical evaluations of in vivo implants 
The harvested implants were rinsed 3 times with PBS and fixed in neutral-buffered formalin solution 
(10%) at RT for 48 hours. The samples were then decalcified using decalcifying solution B (Wako Pure 
Chemical Industries, Ltd.) for 48 hours and dehydrated in serial dilutions of ethanol. The samples were then 
embedded in paraffin, cross-sectioned at thickness of 7 µm and deparaffinized. The cross-sections were 
stained with hematoxylin and eosin (H&E, MUTO Pure Chemicals CO., Ltd.) solution and observed under a 
light microscope. 
The cross-sections were also immunohistochemically stained for von Willebrand factor (vWF), VEGF 
and osteocalcin (OCN). For staining of vWF and VEGF, the deparaffinized cross-sections were performed 
heat-mediated antigen retrieval with citrate buffer (pH 6.0) for 15 minutes. For staining of OCN, the 
deparaffinized cross-sections were incubated with proteinase K for antigen retrieval for 10 minutes. Then all 
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the cross-sections were incubated with peroxidase blocking solution 5 minutes and goat serum solution 
(10%) 30 minutes. Subsequently, the cross-sections were respectively incubated with primary antibodies of 
rabbit monoclonal anti-human von Willebrand factor (working concentration, 1: 100; Abcam), rabbit 
monoclonal anti-human VEGFA (prediluted; Abcam) and rabbit polyclonal anti-human osteocalcin (working 
concentration, 5 μg/mL; Abcam) for 2 hours. After washing with PBS for three times, the cross-sections were 
incubated with peroxidase-labeled polymer-conjugated secondary antibodies (Cytomation EnVision+, Dako) 
for 1 hour, followed by incubation with 3,3’-diaminobenzidine (DAB; Liquid DAB+ Substrate Chromogen 
System, Dako) for 10 minutes for color development. Hematoxylin was used to counterstain the nuclei. All 
procedures were carried out at RT. The stained samples were observed under a light microscope. 
4.3.9 Evaluation of microvessel density (MVD) 
Microvessel density (MVD) has been widely performed to evaluate angiogenesis level in tumor models 
and pathological specimens using endothelial cell markers such as vWF or CD34 [13]. Quantification of 
MVD was performed for the cross-sections after immunohistochemical staining of vWF. Photomicrographs 
at a magnification of 200× from 5 randomly selected regions of the stained cross-sections were used to 
calculate the microvessels in each of these regions using an Image-Pro Plus software (Media Cybernetics, 
Inc.). The brown-stained lumen-like structures were counted as individual microvessels. The data were then 
processed for statistical analysis. The average value from the 5 regions was regarded as the MVD level of 
each cross-section. 4 samples and every 4 cross-sections of each sample were used for the analysis.  
4.3.10 PCR assay for in vivo implants 
Expression of angiogenesis-related and osteogenesis-related genes encoding human-VEGF, KDR (a 
receptor of VEGF), bone morphogenetic protein-2 (BMP-2) and bone sialoprotein 2 (IBSP) was analyzed by 
real-time PCR (RT-PCR). After 8 weeks of implantation, the surrounding soft tissue of the harvested 
implants was cleaned. The implants were then rinsed 3 times with PBS and frozen in liquid nitrogen, 
followed by crushing into powder and dissolving in Sepasol solution (Nacalai Tesque, Inc.) to isolate RNA 
from the cells. A first stand cDNA synthesis kit (Applied Biosystems) was used to convert RNA to cDNA. 
The RT-PCR was performed on a 7500 Real-Time PCR system (Applied Biosystems) [14]. Expression of 
GAPDH was used as an endogenous standard. Relative gene expression was detected by using the formula 
2-ΔΔCt. The gene expression of cells in the DEX-BCP-Col composite scaffold without microgrooves was used 
as a reference. Each experiment was carried out in quadruplicate. Primers and probes are listed in Table 4.1.   
 
Table 4.1. The primers and probes for real-time PCR. 
 
mRNA Oligonucleotide 
GAPDH Hs99999905_m1 
VEGF Hs00900054_m1 
KDR Hs00911705_g1 
IBSP Forward 5’-TGCCTTGAGCCTGCTTCC-3’ 
Reverse 5’-GCAAAATTAAAGCAGTCTTCATTTTG-3’ 
Probe 5’-CTCCAGGACTGCCAGAGGAAGCAATCA-3’ 
BMP-2 Hs00154192_m1 
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4.3.11 Statistics analysis 
All quantitative data expressed as the mean ± standard deviation (SD) were analyzed using Kyplot 
software (version 2.0 beta 15). One-way ANOVA statistical analysis was performed to evaluate the 
significance of the experimental data, followed by a Tukey’s post hoc test for pairwise comparison. When the 
p-value was less than 0.05, the difference was considered as significant. The data were indicated by * p < 
0.05, ** p < 0.01 and *** p < 0.001. 
4.4 Results 
4.4.1 Preparation and characterization of NPs and microgrooved composite scaffolds 
DEX@BCP NPs were prepared by reacting DEX-contained Ca(NO3)2·4H2O aqueous solution with 
(NH4)2HPO4 aqueous solution. TEM observation showed the DEX-BCP NPs were short rod-like and had a 
dimension of 5-25 nm in width and 20-80 nm in length (Fig. 4.2a). The microgrooved DEX@BCP/Col 
composite scaffolds were manufactured by mixing DEX-BCP NPs, collagen aqueous solution and ice 
particulates and placing micropatterned templates on the top of the mixture. The constructs were freeze-dried 
and cross-linked to obtain the composite scaffolds. Parallel ice lines or ice network with different dimensions 
and intervals were used as templates to introduce the microgrooves into the scaffolds (Fig. 4.3a and c). The 
flat template without ice lines or ice network was used to prepare a control composite scaffold without 
microgrooves. Scaffolds with 5 types of microgrooves were prepared by using the respective templates (Fig. 
4.3b and d).  
SEM observation showed that the basal layers of the composite scaffolds were composed of porous 
DEX-BCP-Col composites and the top layers were composed of microgrooved collagen thin sheets. For 
basal layer of each scaffold, they all had abundant spherical large pores, most of which were interconnected 
by small pores (Fig. 4.3b and d, vertical; Fig. 4.2b and c). Dimension of the spherical large pores was almost 
equal to the dimension of the pre-prepared ice particulates used as a pore-forming agent. The small pores 
provided good interconnections among the large pores. The good interconnectivity should be beneficial for 
migration and spatial distribution of the cells. The surface of the large pores was rough and the DEX-BCP 
NPs were homogeneously embedded in the collagen matrices (Fig. 4.2d). The top layer had different types of 
microgrooves. The composite scaffolds had parallel microgrooves with a same concave width of 290 ± 21 
µm and a different convex ridge width of 47 ± 8, 153 ± 15 and 352 ± 23 µm were designated as W1G1, 
W1G2 and W1G3, respectively. The composite scaffolds had parallel microgrooves with a concave width of 
493 ± 30 µm and a convex ridge width of 357 ± 14 µm was designated as W2G3. The composite scaffolds 
had networked microgrooves with a concave width of 297 ± 17 µm and a convex ridge width of 346 ± 11 µm 
was designated as Network. The microgrooves in cross-sections showed a semicircular shape, which was 
replicated from the ice lines. The control scaffold that was designated as Flat had a relatively smooth top 
surface. 
4.4.2 Cell adhesion and distribution in composite scaffolds 
Cell adhesion in the Flat, W1G1, W1G2, W1G3, W2G3 and Network composite scaffolds after 1 day 
culture was investigated by SEM (Fig. 4.4a). The hMSCs well adhered on the spherical large pores of the 
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composite scaffolds. HUVECs well adhered on the convex ridges as well as the concave microgrooves of the 
microgrooved composite scaffolds. HUVECs randomly adhered on flat surface of the control composite 
scaffold. All the cells spread widely with many filopodia. The adhesion and morphology of the cells in the 
composite scaffolds indicated that the scaffolds supported cell adhesion and spreading. Assembly of 
HUVECs on the microgrooves of the composite scaffolds was observed by DAPI staining and 
immunofluorescent staining of human-CD 31 after in vitro culture for 3 days (Fig. 4.4b and c). HUVECs on 
the Flat composite scaffold showed a random distribution. For the microgrooved composite scaffolds, 
HUVECs distributed predominantly in the concave microgrooves and fewer cells were observed on the 
convex ridges. HUVECs assembled and formed cell bands along the direction of the microgrooves. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2. Morphology of DEX-BCP NPs and microporous structure of DEX-BCP/Col composite scaffolds. 
(a) Morphology of the prepared DEX-BCP NPs. (b) and (c) SEM images of the cross-sections of the basal 
layer of W1G3 scaffold at low and high magnifications. (d) SEM image of the pore surface of W1G3 
scaffold.    
4.4.3 Gross appearance and histological analysis of in vivo implants 
Every two same cells/scaffold constructs were stacked into one implant and subcutaneously implanted 
into dorsa of nude mice for 8 weeks. No obvious inflammation was observed during the implantation. Gross 
appearance of the implants is shown in Fig. 4.5a. The two stacked composite scaffolds were connected 
tightly with each other and no obvious malposition was found. There was no evident change of the shape for 
all the implants. All implants showed reddish color, which should be due to the formation of blood vessels 
within the scaffolds.  
H&E staining showed uniform cell and matrix distribution throughout all the implants (Fig. 4.5b). After 
8 weeks, the new blood vessels that were recognized by existence of lining endothelial cells and red blood  
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Fig. 4.3. Preparation of microgrooved DEX-BCP-Col composite scaffolds. (a) and (c) Images of ice line 
templates with different dimensions and intervals prepared from water dispensing. (b) and (d) SEM images 
of microgrooved DEX-BCP-Col composite scaffolds. Flat: control DEX-BCP-Col composite scaffold 
without microgrooves. W1G1, W1G2 and W1G3: DEX-BCP-Col composite scaffolds bearing parallel 
microgrooves with a same concave width of 290 ± 21 µm and a different convex ridge width of 47 ± 8, 153 ± 
15 and 352 ± 23 µm. W2G3: DEX-BCP-Col composite scaffolds bearing parallel microgrooves with a 
concave width of 493 ± 30 µm and a convex ridge width of 357 ± 14 µm. Network: DEX-BCP-Col 
composite scaffold bearing cross network of microgrooves with a concave width of 297 ± 17 µm and a 
convex ridge width of 346 ± 11 µm. For (b) and (d), upper images show the top view and lower images show 
the vertical cross-sectional view of different scaffolds.    
 
cells, were observed in all the groups (yellow triangles in Fig. 4.5b). The new blood vessels were observed 
through all the regions in the microgrooved scaffold implants, while they were observed only at the 
peripheral regions of the control scaffold. Among the 5 types of implants bearing microgrooves, angiogenesis 
appeared to be more evident in the W1G3 and Network scaffolds. At a high magnification, blood vessels 
with different sizes were observed (Fig. 4.6). Some of the blood vessels in the central regions of the implants 
were as large as 220 µm. Meanwhile, new bone formation was also observed in all the implants (green 
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triangles in Fig. 4.5b). The newly formed bone was only in peripheral regions of the Flat composite scaffold, 
while distributed in whole regions of the microgrooved composite scaffolds. In accordance with the degree 
of angiogenesis, the degree of osteogenesis appeared to be higher in the Network and W1G3 scaffolds than 
did in other scaffolds. When compared to the W1G3 scaffold, the angiogenesis level and area of newly 
formed bone in the Network scaffold were even higher (Fig. 4.5b, Fig. 4.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.4. Cell adhesion and distribution in the scaffolds. (a) SEM images of the composite scaffolds after 1 
day in vitro culture. Cells in the top layer and basal layer of the scaffolds are shown at low and high 
magnifications. (b) Distribution of HUVECs after 3 days culture. Blue fluorescence: cell nuclei labelled by 
DAPI. (c) Assembly of HUVECs in the microgrooves after 3 days culture. Red fluorescence: HUVECs 
labelled by human-CD 31. Blue fluorescence: cell nuclei labelled by DAPI.    
4.4.4 MVD of the implants 
To further visualize the newly formed blood vessels within the implants, the histological sections of the 
implants were immunohistochemically stained with vWF, which is one kind of the endothelial cell markers 
(Fig. 4.7a). The brown-stained lumen-like structures were considered as individual vessels. The newly 
formed blood vessels were observed in both peripheral regions and central regions of the microgrooved 
scaffolds. However, they were only observed in the peripheral regions of the control scaffold. The MVD 
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within the implants was then quantified and the results demonstrated that the dimension of microgrooves 
influenced the density of the newly formed blood vessels (Fig. 4.7b). The MVD of W1G1, W1G2, W1G3 
and Network scaffolds was significantly higher than that of Flat scaffold. For the 5 types of microgrooved 
composite scaffolds, angiogenesis degree was also different. The Network and W1G3 composite scaffolds 
showed higher level of MVD, suggesting the concave width and convex ridge width of W1G3 and Network 
scaffolds were most suitable for the assembly of HUVECs to promote regeneration of blood vessels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.5. Gross appearance and histological analysis of the implants. (a) Gross appearance of the implants 
after in vivo implantation for 8 weeks. (b) Photomicrographs of H&E staining of the decalcified 
cross-sections of the implants. The photomicrographs in the second line are the magnified ones of the first 
line. The photomicrographs in the third and fourth lines are the magnified ones at peripheral and central 
regions of the photomicrographs shown in the second line. Yellow triangles indicate new blood vessels. 
Green triangles indicate new bone formation.   
4.4.5 Immunohistochemical staining of angiogenesis- and osteogenesis-related proteins 
To detect the presence of angiogenesis- and osteogenesis-related proteins, immunohistochemical 
staining of VEGF and OCN was carried out for the implants. As a typical angiogenic growth factor, VEGF 
can induce the migration and proliferation of endothelial cells, leading to the formation of tubular structure 
[15]. The VEGF protein was detected in all the implants at different levels (Fig. 4.8). Expression of VEGF in 
the microgrooved scaffold implants was much higher than that in the Flat scaffold implant. VEGF showed 
the highest expression in the Network and W1G3 scaffolds. In comparison to the Flat scaffold, VEGF 
showed more homogeneous distribution pattern throughout all the regions of the microgrooved scaffolds. 
Expression of VEGF was most homogenous in the Network and W1G3 scaffolds. OCN is secreted 
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exclusively by osteoblasts and is involved in bone mineralization and calcium ion homeostasis [16]. OCN 
was also expressed in all the implants at different levels (Fig. 4.9). Expression of OCN was detected only at 
the very edge of the Flat scaffold, while was detected throughout the whole construct of all the microgrooved 
composite scaffolds. Especially, similar to the expression of VEGF, the expression of OCN was higher and 
more uniform in the Network and W1G3 scaffolds. The results of immunohistochemical staining of VEGF 
and OCN indicated that both angiogenesis and osteogenesis degree were up-regulated by the microgrooves 
in the composite scaffolds, among which the Network scaffold showed the highest angiogenesis and 
osteogenesis degree, followed with the second highest degree of W1G3 scaffold.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6. Photomicrographs of H&E staining of the decalcified cross-sections of the 8 weeks implants at a 
high magnification of the peripheral and central regions. Yellow triangles indicate new formed blood vessels. 
4.4.6 Expression of angiogenesis- and osteogenesis-related genes 
Expression of angiogenic and osteogenic marker genes after in vivo implantation for 8 weeks was 
analyzed by RT-PCR (Fig. 4.10). Expression of VEGF was significantly up-regulated in all microgrooved 
scaffold implants in comparison with the Flat scaffold implant. Expression of KDR was significantly 
up-regulated by the Network scaffold. Expression of IBSP was significantly up-regulated by the W1G2, 
W1G3 and Network scaffolds. Expression of BMP-2 was significantly up-regulated by the W1G3 and 
Network scaffolds. For the 5 types of microgrooved scaffolds, up-regulation of the angiogenic and 
osteogenic genes were shown at different level, among which the Network scaffold showed the highest level 
and the W1G3 scaffold was the second highest. 
4.5 Discussion 
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Bone defect is one of the most common diseases that threaten public health. In recent decades, instead of 
allografts and autografts, more and more studies have been focused on artificial bone substitutes with 
suitable biological properties for repair of large size bone defects. However, the current bone substitutes are 
facing with some challenges, among which the two most crucial issues are the deficiency of mature vascular 
networks within the bone substitutes to transport nutrients, oxygen and signal molecules for the rapid 
osteogenesis [17], and the sustained and prolonged release of valid osteogenic cues to promote and 
implement the long-term bone regeneration. In the present study, microgrooved DEX-BCP-Col composite 
scaffolds were prepared to overcome the two problems mentioned above. Compared to the Flat scaffold 
without microgrooves, the composite scaffolds bearing parallel microgrooves or microgroove network 
showed promoted effects on the angiogenesis and osteogenesis. The microgrooves together with released 
DEX, Ca2+ and PO43- were beneficial for simultaneous angiogenesis and osteogenesis. Vascular endothelial 
cells (VECs) are polarized cells that have an apical surface that excludes adhesion to ECM proteins and a 
basal surface that adheres to the underlying basement membrane proteins [18]. The cell polarity can make 
VECs to assemble into capillary-like networks when they are cultured on ECM matrix such as collagen [19]. 
In the preset study, the microgrooves could induce the assembly of HUVECs along the microgrooves and 
therefore stimulate the regeneration of blood vessels. Regeneration of blood vessels could improve the 
supply of nutrients and removal of metabolic wastes and therefore promote migration, proliferation and 
osteogenic differentiation of hMSCs. The synergistic effects from microgrooves and released DEX, Ca2+ and 
PO43- further promoted bone tissue regeneration after implantation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.7. Quantification of the newly formed blood vessels in the implants. (a) Immunohistochemical 
staining of vWF in the peripheral and central regions of the implants. The brown signals show the presence 
of vWF. (b) The microvessel density (MVD) within the implants. The MVD was quantified by using the 
cross-sections immunohistochemically stained for vWF. Data represent mean ± SD, N = 4. Significant 
difference: * p < 0.05; ** p < 0.01; *** p < 0.001. 
 
To investigate the effect of microgroove structure on angiogenesis, microgrooves having different 
concave widths or convex ridge widths or cross network were designed and used for a comparison. At first, 
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the effect of microgroove convex ridge width was compared by keeping the concave widths of the 
microgrooves at the same level. The W1G1, W1G2 and W1G3 scaffolds bearing microgrooves of the same 
concave width (290 µm) but different convex ridge widths (47 ± 8, 153 ± 15 and 352 ± 23 µm) were 
prepared and used for 3D cell culture and implantation. HUVECs well adhered and assembled along the 
microgrooves in the W1G1, W1G2, and W1G3 scaffolds. The W1G3 scaffold had better promotion effect on 
the angiogenesis than did the W1G1 and W1G2 scaffolds. A wider convex ridge width (352 ± 23 µm) was 
better for angiogenesis. The convex ridge widths reflected the gaps between the microgrooves. The large 
gaps between the microgrooves (W1G3) could isolate the assembled cells in the microgrooves to facilitate 
formation of microtubular structures. On the other hand, the small gap (W1G1) could not maintain the 
integration of the assembled cells in the microgrooves and therefore might result in large cell sheets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8. Immunohistochemical staining of VEGF. The brown signals show the presence of VEGF in the 
cross-sections of the implants. The photomicrographs in the second and third lanes are the magnified ones at 
peripheral and central regions of the implants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.9. Immunohistochemical staining of OCN. The brown signals show the presence of OCN in the 
cross-sections of the implants. The photomicrographs in the second and third lanes are the magnified ones at 
peripheral and central regions of the implants. 
 
The effect of concave widths of the microgrooves was compared by changing the concave width from 
290 ± 21 µm (W1G3) to 493 ± 30 μm (W2G3) while keeping the convex ridge width of microgrooves at the 
same level (W1G3: 352 ± 23 µm; W2G3: 357 ± 14 µm). W2G3 scaffold had lower promotion effect on 
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angiogenesis than did the W1G3 scaffold. Angiogenesis in W2G3 scaffold was even lower than that of 
W1G1 and W1G2 scaffolds. The results indicated that the concave width of the microgrooves had very 
evident effect on angiogenesis. The concave widths of the microgrooves reflected curvature of the 
semi-spherical microgrooves. Lower concave width resulted in larger curvature. It has been demonstrated 
that curvature could affect cell-cell interaction thus to play a role for tissue alignment [20]. High curvature is 
favorable for the formation of functional multicellular structures and large-scale highly organized and 
aligned tissues [21]. Concave microgrooves could guide the assembly of HUVECs in a contractile stress 
dependent manner [22]. Initially, upon HUVECs spreading on the microgrooves, they aligned along the main 
axis of the microgrooves. And then, the cells spread to contact the adjacent cells, formed cell-cell junctions 
and, due to the geometric constraints within them, exerted 3D traction forces along the direction of the 
microgrooves [23]. The cell-cell junctions between endothelial cells plays a critical role in transmitting 
contraction stresses [24] and generation of a mechanically balanced structure (i.e., bundles) [25]. The smaller 
width of the concave microgrooves hence the higher curvature in W1G3 scaffold could increase cell-cell 
interaction to strongly stimulate cell assembly along the long axis of the microgrooves to facilitate 
regeneration of blood vessels. The cross network of microgrooves in Network scaffold had the same concave 
width and convex ridge width as those of the W1G3 scaffold. The promotion effect on angiogenesis by 
Network scaffold was the highest among the 5 types of microgrooved scaffolds. The superiority of Network 
scaffold to W1G3 and the other scaffolds should be due to the microgroove network in Network that could 
provide more opportunity for the HUVECs to assemble to network structure for promotion of angiogenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.10. Gene expression of human VEGF (a), KDR (b), IBSP (c) and BMP-2 (d) of the cells in the 
implants. Data represent mean ± SD, N = 4. Significant difference: * p < 0.05; ** p < 0.01; *** p < 0.001. 
 
It has been widely established that angiogenesis can promote osteogenesis [26, 27]. The osteogenesis 
promotion effect of the microgrooved composite scaffolds and control scaffold was in a good accordance 
with their promotion effect on angiogenesis. The Network scaffold showed the best effect on angiogenesis 
and osteogenesis, followed by W1G3 scaffold. Besides the promotion effect from the microgrooves, release 
of DEX, Ca2+ and PO43- from the composite scaffolds should also have stimulative effect on osteogenic 
differentiation of hMSCs and new bone tissue formation. Degradation of DEX-BCP NPs in the composite 
scaffolds resulted in the sustained release of DEX, Ca2+ and PO43-, which could function synergistically to 
up-regulate the expression of osteogenic genes and proteins [11], leading to the osteogenic differentiation of 
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hMSCs and the final osteogenesis of the whole constructs. It’s noticeable that the ultimately effective blood 
vessel formation and new bone regeneration in the composite scaffolds should be contributed to the close 
association and interaction between angiogenesis and osteogenesis. In one aspect, most osteogenic factors 
involved in osteogenesis, such as BMP-2, can stimulate angiogenesis either directly or indirectly, by 
generating angiogenic molecules such as VEGF, which is involved in angiogenesis [28]. On the other hand, 
VEGF stimulates osteoblast differentiation and inhibits osteoblast apoptosis [29]. Mutual promotion of 
angiogenesis and osteogenesis by the microgrooved DEX-BCP-Col composite scaffolds accomplished the 
rapid ectopic new bone formation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.11. Photomicrographs of H&E staining of the decalcified cross-sections of the W1G3 and Network 
implants after 8 weeks implantation at low and high magnifications. Yellow triangles indicate new blood 
vessels. Green triangles indicate new bone formation. 
 
Although some approaches have been explored to enhance the angiogenesis and osteogenesis of the 
scaffolds for bone tissue engineering, the strategy declaimed in the present study exhibited obvious 
advantages. Currently, most of the scaffolds designed to control the cell orientation are prepared partially or 
completely from non-bioactive materials. Microgrooved substrates have been made from silicon [30], 
silicone rubber [31], titanium [32], quartz [33], acrylic [34], epoxy resin [35], polystyrene [36], and 
poly-lactic acid and its derivatives [37]. Whereas, in this study, the microgrooved scaffolds were prepared 
from a natural biological material, i.e., type I collagen. Collagen has many advantages such as high 
bioactivity, good integration of healing tissues, lowest immune and foreign-body responses, non-cytotoxicity 
and good biodegradation [38]. It can provide biological cues to regulate cell migration, proliferation and 
vascular morphogenesis of vascular endothelial cells [39]. Moreover, in our work, the pre-prepared ice lines 
were used as the templates to prepare the microgrooves. This method did not require conjugation of 
angiogenic factors and cell adhesion ligands within the scaffolds. The microfabrication technique was a 
simple and mild process without usage of any toxic solvent. In addition, the microgrooved DEX-BCP-Col 
composite scaffolds prepared in our work successfully integrated angiogenesis and osteogenesis in the 3D 
scaffolds, which should provide useful guide for design of the scaffolds for bone tissue engineering. 
4.6 Conclusions 
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Four types of DEX-BCP-Col composite scaffolds bearing parallel microgrooves with different concave 
width and convex ridge width and one type of DEX-BCP-Col composite scaffold bearing microgroove cross 
network were prepared by using pre-fabricated ice lines as templates. The DEX-BCP-Col composite 
scaffolds were used for co-culture of HUVECs and hMSCs for simultaneous promotion of angiogenesis and 
osteogenesis. HUVECs well assembled along the microgrooves. Subcutaneous implantation in nude mice 
showed more angiogenesis and bone formation were observed in the microgrooved composite scaffolds than 
those in the control composite scaffold without microgrooves. The composite scaffolds bearing parallel 
microgrooves with a concave width of 290 µm and a convex ridge width of 352 µm had the highest 
promotion effect among the parallelly microgrooved composite scaffolds. The scaffold bearing microgroove 
cross network surpassed all parallelly microgrooved composite scaffolds. The results suggested that 
microgrooves in the composite scaffolds stimulated angiogenesis and osteogenesis. The microgrooved 
DEX-BCP-Col composite scaffolds should be useful for large bone tissue regeneration.  
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Concluding remarks  
 
 
 
 
  
The research focused on the development of dexamethasone-loaded biphasic calcium phosphate 
nanoparticles (DEX@BCP NPs) and their composite scaffolds with collagen and exploring their applications 
in bone tissue engineering. DEX was loaded in BCP NPs either during BCP formation or after BCP NPs 
formation. The optimized DEX@BCP NPs were hybridized with collagen sponges to prepare their composite 
scaffolds (DEX@BCP/Col). The composite scaffolds were used for culture of human bone marrow-derived 
MSCs (hMSCs) to investigate their effects on osteogenic differentiation of hMSCs and bone regeneration. To 
further enhance the osteogenesis and angiogenesis of the DEX@BCP/Col, microgrooved networks were 
introduced in the scaffolds. The microgrooved scaffolds were seeded with HUVECs and hMSCs then 
subcutaneously implanted in nude mice. The formation of the new bone and blood vessels within the 
scaffolds was checked after 8 weeks’ implantation. 
 
Chapter 1 introduces and summarizes the composition and function of natural bone and the commonly 
used methods for bone defect repair. Among all the methods, more emphasis is placed on the bone tissue 
engineering. The three fundamental principles for bone tissue engineering are then given, i.e., the scaffolds, 
the cells and the bioactive molecules. Afterwards, the up-to-date strategies used in bone tissue engineering 
are highlighted. Design and preparation of biomimetic multiple-functional scaffolds for bone tissue 
engineering is then motivated.  
 
 Chapter 2 summarizes the design and preparation of DEX-loaded BCP NPs. DEX-loaded BCP NPs 
were prepared by two methods: (1) immersion of BCP NPs in a DEX solution (defined as DEX/BCP NPs), 
(2) DEX incorporation during BCP NPs formation in a calcifying solution (defined as DEX@BCP NPs). The 
DEX@BCP NPs showed higher DEX loading amount and more sustainable DEX release than did the 
DEX/BCP NPs. The DEX@BCP NPs were used for culture of hMSCs and showed a promotive effect on 
proliferation of hMSCs. Furthermore, the DEX@BCP NPs significantly increased the alkaline phosphatase 
(ALP) activity, calcium deposition and gene expressions of osteogenic markers of hMSCs when compared to 
BCP NPs without DEX loading. The results demonstrated BCP NPs are a good carrier for DEX and the 
DEX@BCP NPs should have potential applications in bone tissue engineering. 
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Chapter 3 summaries the preparation of DEX@BCP NPs/collagen composite scaffolds and their effects 
on bone tissue engineering. The DEX@BCP NPs were introduced into the porous composite scaffolds of 
collagen. The obtained DEX@BCP NPs/collagen scaffold (DEX@BCP/Col) showed high mechanical 
strength, a controlled and sustained release nature of DEX, as well as a controlled pore structures resulting 
from using ice particulates as a porogen material. The composite scaffolds showed good biocompatibility 
and promoted osteogenic differentiation of hMSCs when used for three-dimensional culture of hMSCs. 
Subcutaneous implantation of the DEX@BCP/Col composite scaffolds at the dorsa of athymic nude mice 
demonstrated that the composite scaffolds facilitated ectopic bone tissue regeneration.  
 
Chapter 4 summarizes the preparation and application of the DEX@BCP/Col composite scaffolds 
having several types of concave microgrooves to the scaffolds in aim of simultaneously enhancing 
angiogenesis and osteogenesis of the scaffolds. The microgrooves in the composite scaffolds were supposed 
to guide assembly of HUVECs into well aligned tubular structures, thus promoting rapid angiogenesis. The 
scaffolds were used for co-culture of HUVECs and hMSCs. Subcutaneous implantation in mice showed that 
more blood vessels and newly formed bone were observed in the microgrooved composite scaffolds than the 
control scaffold without microgrooves. The composite scaffolds bearing parallel microgrooves with a 
concave width of 290 µm and a convex ridge width of 352 µm had the highest promotion effect on 
angiogenesis and osteogenesis among the parallelly microgrooved composite scaffolds. The microgroove 
network had further superior effect than the parallel microgrooves. The results suggested that microgrooves 
in the composite scaffolds facilitated angiogenesis and stimulated new bone formation.  
 
In summary, in the research the DEX@BCP NPs with a sustained release profile were prepared and 
their influence on osteogenic differentiation of the hMSCs was confirmed by in vitro culture of hMSCs. 
Then, the prepared DEX@BCP NPs were hybridized into porous collagen scaffolds and their potential for 
bone tissue engineering was investigated. The excellent pore structure, enhanced mechanical property of the 
DEX@BCP/Col composite scaffolds, as well as the sustained release of DEX from them synergistically 
facilitated the osteogenic differentiation of hMSCs and new bone tissue regeneration during in vitro culture 
and in vivo implantation. The DEX@BCP/Col composite scaffold with the highest DEX loading amount 
showed the most promising potential for bone tissue engineering. Afterwards, to further enhance the 
angiogenesis and osteogenesis, DEX@BCP/Col composite scaffolds with microgroove network were 
designed and prepared. The results suggest that microgrooves in the composite scaffolds facilitated 
angiogenesis and promoted new bone formation. The composite scaffolds with the microgroove network 
showed the highest effects. The DEX@BCP NPs/collagen porous composite scaffolds should be useful for 
three-dimensional culture of stem cells for osteogenic differentiation and bone tissue engineering. 
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